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Abstract 
Biological protein assemblies are the products of evolutionary necessity that 
have arisen to protect the cell, improve reaction rates, and/or compartmentalize 
biological systems. Belonging to this category of sel-assembling bionano-
structures are cage proteins. Cage proteins are composed of multiple protomers 
(subunits) that self-assemble into many unique structures, all having interior, 
exterior, and interface surfaces available for controllable modification. 
Bacterioferritins (Bfr) are a set of cage proteins belonging to the ferritin 
superfamily of iron storage proteins, are roughly spherical with a 12 nm exterior 
diameter and an 8 nm interior diameter, are composed of 24 identical protomers, 
and contain 12 heme cofactors. An important feature of Bfr that was utilized for 
advancement in platform development was the locality of the N- and C- termini. 
These termini point towards the exterior and interior of the protein cage, which 
made them ideal for genetic engineering these two surfaces. Polyhistidine amino 
acid sequences (His6-tags) were added to the C-termini of the Bfr protein 
subunits in order to provide new selective affinity interactions on the interior 
protein surface of this multiprotein cavity. This His6-tag affinity interaction 
allowed for Ni2+-dependent complexation between the host Bfr and two guest 
molecules modified with a nitrilotriacetic (NTA) acid. The two proof of concept 
guests studied in our laboratory were streptavidin binding a biotin-XNTA 
functionality, and a gold nanoparticle (GNP) containing NTA functionalities. 
This approach was designed to make both streptavidin and GNPs addressable to 
the interior surface of Bfr through the NTA/His6-tag affinity interaction. The 
purpose of these experiments was to explore various methodologies to form 
controllable interactions between guest molecules and internal protein cavity 
surfaces. Additionally, the endogenous heme molecules were exchanged for 
fluorescently-modified hemes as a further approach to engineer this cage protein 
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for host-guest interactions. The information gained from the above experiments 
will help develop the bionanotechnology applications of Bfr.  
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1. Chapter 1: Introduction 
1.1. Summary of Research 
Although proteins are complex molecules, they can be engineered and 
repurposed through a combination of recombinant genetic and chemical 
approaches. Multiprotein complexes, such as cellular housekeeping cage 
proteins and viral coat proteins fall within the category of bio-nanoparticles, 
and are being investigated with intense interest as potential platforms for 
drug delivery, unique materials generation, biosensors, and other novel 
applications.1-5 These protein shells vary in size from the largest virus with a 
750 nm diameter shell to the smaller protein complexes with diameters of 10 
nm 6,7 (Figure 1.1). This diversity in size, and function, provides a reservoir 
of cage proteins all governed by similar assembly principles, which could be 
used in many unique applications. Of importance to these applications is 
understanding how host-guest interactions are central for encapsulating 
novel guest molecules, which modifications to the protein cage outer surface 
can be made to direct it to particular surfaces, and how native features can 
be exploited to the user’s advantage.   
The purpose of the proposed experimental research described herein was 
to better characterize the properties and limits of one such biomolecular 
system, bacterioferritin (Bfr), as a platform for host-guest interactions and 
surface targeting. This entailed three major areas of investigation: 
engineering of host-guest encapsulation interactions, surface targeting by 
protein cage modifications, and chemical modification of propionate groups 
on the native heme cofactor. In this chapter, the application of bio-
nanomolecular systems will be outlined, and the relevant background 
information on cage proteins, encapsulation strategies, and labeling 
cofactors will be discussed.  
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Figure 1.1: Size comparison of three commonly cited cage proteins investigated compared to a 
C60 fullerene. From left to right are the vault protein, CCMV, Bfr, and a C60 fullerene. Images 
were generated in Pymol using PDB IDs: 2QZV, 1CWP, and 1BFR.   
 
1.2. Biological Molecules in Nanotechnology: The Emergence of 
Bionanotechnology-Driven Applications  
1.2.1. Encapsulation of Functional Guests in Cage Proteins 
Host-guest interactions, or the methods to encapsulate guest 
molecules within protein cages are essential in the design of drug delivery 
vehicles, nano-reactors, and unique biomolecular platforms. Understanding 
the methods used to encapsulate guest molecules will be important for future 
development of successful host-guest interactions. Presented below will be a 
discussion of three methods of encapsulation along with the various unique 
features of hosts that are exploited to encapsulate targeted guests.  
Encapsulating novel guest molecules within a cage protein remains a 
challenging pursuit. Developing methodologies to probe the capabilities of 
host cage proteins remains an important, but poorly understood area. This 
point was emphasized by J. Cornelissen in his Nature Chemistry publication 
on viral encapsulation wherein he highlighted that outer surface 
modifications to cage proteins are generally much easier than the series of 
careful choices that must be made for successful encapsulation, and proper 
host interaction with the guest8. Methodologies to encapsulate guest 
molecules, generally, require disassembly of the protein cage, which allows 
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guest molecules to interact with the interior surface of the host. Once the 
guest interacts with the interior of the host surface, reformation of the cage 
permits the trapping and encapsulation of the target guest molecule(s). The 
contacts that maintain the host and guest interaction can be subdivided into 
three categories: concentration dependent encapsulation, covalent or 
genetically engineered linkages, and non-covalent affinity interactions 
(Figure 2). Presentation of examples will be given here to exemplify each 
category. 
 
 
Figure 1.2: Demonstration of the three categories of encapsulation methods. The first method 
(A) is non-specific and only passively accumulates guest molecules. The second method (B) uses 
a covalent linker to associate guest molecules to the interior through genetically engineering, a 
covalent modification (R) to amino acids, or either genetic or chemical linkage to scaffolding 
proteins (*). The third type (C) is a specific, and non-covalent method of encapsulation. 
1.2.1.1. Concentration Dependant Encapsulation 
This first category is less well represented in the literature because it 
is an unspecific method. The methodology involves the disassembly of the 
host cage protein in the presence of high concentrations of the desired guest 
molecule (Figure 2A). Upon reassembly of the host cage protein some 
population of guest is encapsulated through mere chance. This method is 
less desirable because there is no driving attractive force between host and 
guest, and so minor repulsive forces preventing the guest from interacting 
with the host can be unfavourable for encapsulation. Cowpea chloritic 
 
A 
B 
C 
* 
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mosaic virus (CCMV) was able to encapsulate horseradish peroxidase using 
this non-specific technique.9 Triggering of CCMV to disassemble was 
accomplished by a switch in the pH, incubation with the guest enzyme, and 
then adjustment of the pH to reform the CCMV capsid. Encapsulation of a 
small molecule drug cisplatin in ferritin was performed by adding cisplatin 
in high concentrations, followed by dissociating ferritin with an alkaline pH, 
and was then re-assembled by decreasing the pH.10  Some other papers 
described similar methods that use excess guest molecule. This is an 
acceptable procedure when the guest can be used in excess amounts, or 
when there is some innate positive interaction already present, such as 
electrostatics or native metal ligation. In these instances, the researcher is 
taking advantage of the intrinsic properties without having to engineer in 
new functionality. Despite the success of this method, more investigations 
have focused on directed encapsulation of guest molecules.  
1.2.1.2. Covalent and Genetically Engineered Encapsulation 
Covalent methods for encapsulation can be used to directly link 
guest molecules to the interior of cage proteins. The interaction is 
irreversible, which can be either disadvantageous or advantageous 
depending on the nature of the application. When the guest molecule is a 
protein or peptide, it is possible to genetically engineer the guest molecule 
onto an associating protein, or to some part of the capsid sequence. The 
Douglas laboratory has used genetic engineering to localize guest proteins to 
the inner surface by modifying a scaffolding protein, which associates to the 
interior of an assembling bacteriophage P22 virus (Figure 2B).11-16 
Scaffolding proteins, as in P22, are highly modular towards incorporation of 
proteins of appropriate sizes. The group has performed studies for the 
purposes of co-expressing and encapsulating aggregation prone guest 
proteins to improve purification techniques. They have encapsulated a wide 
variety of enzymes, such as: CelB glycosidase, alcohol dehydrogenase, and 
have simultaneously encapsulated three enzymes involved in a cascade 
reaction. This methodology excellently utilizes the native scaffolding 
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protein for the purposes of encapsulating guest molecules through covalent 
linkage to the interior surface.  
Direct labelling through covalent modification of an amino acid is a 
familiar method to biochemists, and has been employed in encapsulation of 
novel guest molecules. A photodynamic therapeutic was covalently attached 
to the interior surface of bacteriophage MS2 by incorporation of a Cys 
residue by site-specific mutagenesis of the virus capsid interior, followed by 
reaction with a maleimide functionalized photodynamic therapeutic agent17. 
The host protein with photodynamic payload was directed to cancerous cell 
surfaces by modification of the exterior surface with an aptamer specific for 
the cell surface. Covalent addition was also used to attach a fluorescent dye 
to the interior of a heat shock protein in combination with a peptide that 
targeted macrophages18. The dye was covalently attached to an interior Cys 
residue through a maleimide containing dye, which was able to detect signs 
of atherosclerosis. Cys labelling was also used in bacteriophage P22 to place 
a catalytic initiator on the interior that allowed for the polymerization of 
poly(2-aminoethyl methacrylate) within the confined environment of the 
cage protein19. The controlled nature of polymerization within a cage limited 
the size, and size distribution of the resulting polymers, which can be of 
great interest in the synthesis of narrow molecular weight distributed 
polymers. The specific applications of covalent encapsulation are those that 
do not require a guest molecule to be released. Cell imaging, encapsulation 
of catalysts or enzymes, and some therapeutics work well with covalent 
approaches for encapsulation. Other applications require or benefit from a 
more dynamic interaction for encapsulation.      
1.2.1.3. Non-covalent Directed Encapsulation  
This mode of encapsulation can be further divided into two groups: 
those that use an accessory coat protein, and those that do not. As is 
somewhat familiar in virus capsids, multiple proteins can be involved in 
formation of a complete viral coat (Figure 2C). Scaffolding and accessory 
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proteins exist that associate to the interior and act as excellent handles for 
genetic modification. The Cornelissen group has used this successfully with 
CCMV in the past, using a genetically engineered addition of a leucine 
zipper cognate pair to associate a guest molecule to the interior of CCMV20. 
Similarly, vault associating protein has been used to encapsulate drug 
molecules and gold nanoparticles to the interior using genetic modifications 
to the associating protein to non-covalently link the guest molecule to the 
interior. In the first case the associating protein had an amphipathic helix 
addition to associate lipid nanodisks saturated with drug molecules to the 
interior space of the vault protein21. In the second example a His-tag on the 
vault associating protein interacted with gold nanoparticles displaying a 
nitrilotriacetic acid (NTA) moiety on the surface22. In another example of 
metal coordination, a 5-iodoacetamido-1,10-phenanthroline was labelled to 
the interior of the P22 bacteriophage protein coat, which was shown to 
coordinate the metal templated growth of 1,3-di-1,10-phenanthrolin-5-
ylthiourea23. Genetic mutations were made to interior residues of the P22 
coat protein to generate a K118C and S39C mutant. These Cys mutants were 
covalently labelled with 5-iodoacetamido-1,10-phenanthroline, which could 
co-coordinate a Ni2+ ion with a 1,3-di-1,10-phenanthrolin-5-ylthiourea (bis 
form of-iodoacetamido-1,10-phenanthroline). This was of interest because it 
demonstrated another mode for metal based affinity interactions. Another 
study utilized Rh-norbornadiene and labelled an interior Cys residue on 
ferritin to initiate the polymerization of phenylacetylene24.  
Genetically integrating a binding motif can be a very versatile 
approach to introduce new affinity interactions. A p19 RNA binding protein 
was engineered as a fusion to the HBV virus, which created a chimeric virus 
that could bind siRNA therapeutics25. This was a very versatile development 
because the p19 RNA binding protein could bind multiple types of siRNA 
without having to make modifications to the therapeutic siRNA structure. In 
addition, the surface was functionalized with an RGD cyclic peptide motif 
to address the virus complex to cancerous cells. Similarly, bacteriophage 
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MS2 through the use of the MS2 bacteriophage’s intrinsic RNA binding 
affinity was able to encapsulate multiple therapeutics and deliver them to 
hepatocellular carcinoma cells1. The interaction was able to encapsulate 
cargo containing an RNA motif known to be bound by the interior of MS2 
cargo, which included: quantum dots, therapeutic drugs, siRNA, and ricin 
toxins. Daunomycin and doxorubicin have both been encapsulated within 
ferritin through the incorporation of a poly-aspartic acid sequence, and the 
co-coordination of a Cu between the native metal binding site of ferritin and 
the drug, respectively 2,26. Both technologies showed potential for drug 
delivery, but only the latter was modified with a cyclic RGD peptide and 
evaluated for its ability to target in vitro and in vivo cancerous cells. Non-
covalent interactions between host and guest creates a more dynamic 
interaction, which can be beneficial for release of cargo, but can also be of 
interest for more stable arrangements. 
1.2.2. Drug Delivery 
Bio-nanoparticles encompass a large natural catalog of particles, 
ranging from DNA to lipids to protein, as well as various combinations of 
these. The two areas of research where bio-nanoparticles are most actively 
pursued are the medical and material science fields. Within the medical area 
there are two main projects: drug delivery and imaging, or image 
enhancement27. The bio-nanoparticles used typically have a hollow centre, 
and a surface amenable to modification. This facilitates the protection of a 
drug, contrast agent, fluorescent molecule, or photodynamic therapeutic, 
which is combined with the ability to target cells displaying specific 
antigens, or receptors. The development of these vehicles is a complex 
process necessitating many requirements. An ideal bio-nanoparticle should 
be: stable enough to retain all of its cargo, large enough to be excluded from 
renal clearance but small enough to avoid opsonisation (enhanced 
permeability and retention effect [EPR])28-30, able to carry molecules that 
can be released from the interior upon encountering a target31, have a ligand 
or marker on the surface that is highly specific to the desired target32, is non-
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recognizable by the immune system33,34, contains non-toxic components or 
metabolic products, and likely other factors that have not been accounted 
for.  
Liposomal delivery particles continue to be the largest contributors 
in this area35. Proteins, however, are persistently being explored as potential 
targets due to several advantageous features, some specific only to 
proteins26,36-44. Many proteins are non-toxic, easily metabolized, can present 
polyvalent markers, have sizes that comply with the EPR effect, are stable, 
are amenable to exquisite chemical and genetic modification, have a 
structurally uniform population, are frequently easy to produce, and have 
structural data available with atomic resolution. The protein systems that 
have been reported have included virus-like-particles (VLP) and protein 
cages, which include ferritins, vault protein, GroEL, heat shock proteins 
(Hsp), and other protein cages. Protein cages are not derived from a single 
peptide chain, but many identical, self-assembling units. Repetition of the 
same unit in the structure provides labelling advantages. Modifications 
designed for any one structural unit will be repeated throughout the overall 
structure; in this there is a built-in propensity for avidity. Cage proteins, 
therefore, have a great potential for directed therapeutic delivery.    
Specific drug delivery to diseased cells has the potential to 
revolutionize the way drugs are taken and diminish the side effects seen in 
patients. Advances in drug delivery have not yet replaced the current 
treatment schemes, and much primary research still remains to be 
performed. Currently, cage proteins are being investigated as a small but 
growing subset of delivery vehicles for their ability to encapsulate 
therapeutics, and to target specific cells. For therapeutic delivery the ideal 
scenario is to trap the drug molecule within the vehicle, and upon delivery to 
the target cell release the drug in an unaltered, active form. Some methods 
of encapsulation include disulphide and acid labile linkages45,46. Two 
nonspecific cellular mechanisms exist that will liberate a guest molecule 
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from the host cage protein. One is the reductive nature of the cellular 
environment, which can reduce disulphide bridges. Therefore, any drug 
covalently bound through a disulphide linkage should be released upon 
entering the reducing environment of the cell. The second mechanism relies 
on acid sensitivity, where endocytosed molecules are targeted to the 
lysosome. The lysosome has an acidic environment, and can cause the 
release of acid labile hydrazine linkers. Other linkers include the attachment 
to RNA, which can be released by degradation with RNases. In this case a 
drug is linked to an RNA molecule, which is then readily degraded by 
RNases found in the body47. Peptides can also be degraded by the 
metalloproteinases overexpressed in regions containing solid tumors, which 
can release encapsulated drug molecules48,49.  
Designing triggers to release therapeutics is as important as being 
able to encapsulate drugs that are otherwise not soluble in aqueous 
solutions. Cyclodextrin has been used to associate hydrophobic drug 
molecules within protein cages, which then slowly leach out into the cell 45. 
Poly-aspartic acid has also been used to specifically locate daunomycin to 
the interior of ferritin50. Use of an RNA label to specifically encapsulate 
multiple types of therapeutics, including small molecule drugs, natural 
toxins, and imaging QDs was used as a versatile targeted encapsulation 
method1. All of these methods have a common theme, and that is the use of 
some linker that can be controllably released upon interaction with the 
desired cell type. Some of the studies mentioned here have investigated the 
efficacy of these approaches in mammalian cells and mouse models. These 
studies have reported the accumulation of the active ingredient in the target 
cell type, and an improvement in the therapeutic effect of the drug.  
The second aspect to drug delivery is the need for targeting a unique 
cell type. This has been effectively accomplished by identifying unique or 
over-expressed receptors on the surface of target cells. Protein cages are 
particularly adept for targeting to cells due to their ability to be multiply 
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labelled with ligands or receptors. This ability should greatly increase the 
interaction with a target cell through an effect known as avidity. For solid 
tumors there is an additional effect called the EPR, which results from the 
prolonged circulation and passive accumulation at the sites of “leaky” 
tumors due to epithelial fenestrations and accelerated angiogenesis at solid 
tumors29..  
Viruses have been used in the past, and although many mammalian 
viruses possess the native ability to penetrate cell interiors to deliver their 
genetic payloads, many of the drug delivery vehicles being designed are 
from plant based viruses, or non-viral cage proteins. Therefore, ligands must 
be engineered onto the surface of these cage proteins to direct them towards 
specific cells. Small molecules can be used to target receptors, such as folic 
acid, which binds the folic acid receptor47. A common ligand to target tumor 
surfaces is the arginylglycylaspartic acid (RGD) peptide, which targets 
overexpressed integrin αvβ3 receptors2,25. RDG is a peptide based ligand, and 
hence this sequence can be genetically engineered onto the protein cage 
surface. Peptide based markers are generally easier to place precisely within 
the protein architecture using established molecular genetic techniques. 
Peptide markers include: epidermal growth factor, LyP-1 peptide, SP94 
peptide, and peptides derived from phage display1,47,51,52. Like phage 
display, which can generate affinity peptides for both organic and inorganic 
targets, aptamer technology has arisen as a means to generate highly specific 
receptors for desired targets. Aptamers have been used to label host surfaces 
to direct them to target cells for photodynamic treatment, but this approach 
could be extended to therapeutic delivery as well17. Selecting the appropriate 
cell identifier and the complimentary ligand or receptor will be essential in 
design of drug delivery vehicles to ensure that drugs are appropriately 
addressed.     
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1.2.3. Directed Placement of Novel Metal Centres 
Ferritins and other protein complexes have been utilized for diverse 
generation of metal centres that fall within the categories of quantum dots 
(QDs) and nanoparticles. Generation of QDs or metal clusters remains an 
interesting area of research in materials science since QDs can exhibit 
superparamagnetic, semiconductor, and fluorescent properties53. 
  Marriage of biological molecules with materials through 
bioconjugation serves interesting applications in the creation of biosensors 
and controlled delivery of inorganic nanocrystaline material. Localization of 
ferritin onto silica surfaces has been accomplished by electrostatic 
attraction, for example: ferritin was found to associate with 100 nm spaced 
positive spots using 3-aminopropyltriethoxysilane on silica54. The ability to 
specifically position a single ferritin is an important display of controlled 
placement useful in the area of bioelectronics. These types of delivery 
methods have been applied to floating nanodot gate memory field effect 
transistors by placing mono-layers of semiconductor NP on a transistor, 
which was accomplished through the use of a poly(ethyleneimine)-modified 
transistor that could electrostatically attract ferritin-containing metal cores 
of CoO55,56. A similar approach was used to develop a low-temperature 
polycrystalline silicon thin film transistor flash memory device, again using 
ferritin to ferry metal cores generated in its interior into location to form the 
required mono-layer 57. Ferrying metal cores can be used for more than 
bioelectronics purposes. The generation of a Förster resonance energy 
transfer (FRET) based biosensor was possible by use of specifically placed 
ZnSe NPs on Si substrate, where ferritin acted as the ferry 58. Use of 
encapsulated QDs in viruses can also be utilized for cellular imaging. 
Simian virus 40 protein capsids was employed to encapsulate QDs 
functionalized with DNA ligands, and subsequently used to target cells in 
vitro59. This approach suggests possible use of such biomolecular 
frameworks in cellular imaging, which would utilize the improved 
properties of QD compared to organic fluorophores.  
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1.2.4. Catalytic Confinement  
Encapsulation of catalysts and enzymes into cage proteins for 
development of nano-reactors has revealed some interesting enzymatic 
properties, some of which remain to be fully explained. The ability to study 
single enzyme reaction rates, and to alter the local environment of the 
encapsulated guest molecules may lead to a better understanding of enzymes 
and improvements of enzymatic turnover. There have been a series of 
experiments that have reported that encapsulated enzymes and catalysts 
results in an increase in the catalytic turnover, no change at all, or alteration 
of other kinetic parameters, such as Km. One of the first investigations of 
enzyme encapsulation was that of encapsulating horseradish peroxidase 
(HRP) within CCMV.9 The HRP enzyme was non-specifically encapsulated 
within CCMV and it was determined that each capsid contained only one 
enzyme molecule. The authors did not perform enzymatic studies, but were 
able to demonstrate that enzymes could be encapsulated within a protein 
capsid without totally disrupting enzymatic function. The next level of 
analysis was to encapsulate an enzyme and evaluate the kinetic parameters. 
The school of thought concerning the effects of encapsulation on enzyme 
activity was that substrate turnover should increase because of the apparent 
increase in concentration of substrate or enzyme within the confined capsid 
space. When a substrate leaves the bulk solution and enters a VLP, or 
protein cage, the volume drastically decreases, and hence the concentration 
of the enzyme, the substrate, or both is significantly magnified within the 
viral capsid. Similarly, if multiple enzymes involved in a cascade reactions 
are placed within the confines of a cage protein the rates should increase 
since the substrates and products are “shuttled” from one reaction centre to 
the next. Recent evidence has shed light on the question of how enzyme 
kinetics are effected within the confined molecular space of viral capsids. 
Encapsulation of Pseudozyma antarctica lipase B (PalB) within CCMV was 
shown to have increased turnover compared to the non-encapsulated 
enzyme.60 The researchers encapsulated PalB by a non-covalent coiled coil 
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affinity interaction between the enzyme and the capsid protein. It was 
observed that the activity of PalB was highest when there were fewer 
enzymes encapsulated (one or two). This was suspected to be a result of the 
limitation of substrate transition into the capsid interior and to active sites. 
The Km did not appear to change and so the explanation for increased rates 
at lower enzyme encapsulation numbers was that the reaction rate was 
increased. The results seemed to fit previous work done with enzymes 
within vesicles, where smaller vesicles increased the turnover number of the 
encapsulated enzymes61. Conversely, encapsulation of CelB glycosidase and 
alcohol dehydrogenase within bacteriophage P22 showed no increases in 
turnover between encapsulated and free enzyme.11,13 Encapsulation of 
alcohol dehydrogenase showed a decrease in both turnover and Km, which 
could be a result of over-crowding, as was observed in the case of PalB 
when excess enzyme was present. The optimal amount of PalB was 3.5 fold 
lower than the alcohol dehydrogenase concentrations found in P22, and so 
there may exist an upper limit when considering enzymatic loading. 
Although great improvements to rates of enzyme reactions were not 
observed, the measured enzyme rates do not appear to decrease upon 
encapsulation. Encapsulation within bacteriophage P22 of three enzymes 
involved in the metabolism of lactose was investigated to evaluate the 
principle of proximity effects with co-encapsulated enzymes.15 Interestingly, 
no increase in turnover was observed in the co-encapsulated enzymes from 
the free enzymes and singly encapsulated enzymes. This null result 
prompted further exploration, which resulted in a mathematical model that 
suggested a fine-tuning of the kinetic balance between enzymes. By 
modulating the first enzyme activity with an inhibitor (Tris buffer) the 
combination of enzymes was observed to outperform the individual 
enzymes under the same conditions. This sheds light on the complexities of 
encapsulated enzymes, and some of the misunderstanding in the field. 
Further investigations on both the encapsulation of single enzymes as well 
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as multiple enzymes will enhance the scope and capabilities of studying and 
manipulating these catalysts.  
Even if enzymes do not show improvements in rate after 
encapsulation, capsids could still be useful for enzymatic studies since free 
enzymes have been shown to decrease activity upon attachment to 
surfaces.62,63 Using a cage protein as a scaffold to house the encapsulated 
enzymes and protect them from surface labelling, degradation could 
circumvent the decrease in enzymatic activity due to covalent attachment to 
a surface. 
Parallel to the enzyme encapsulation studies are experiments that 
have been reported on inorganic catalyst encapsulation. One study reported 
the encapsulation of a Pt nanoparticle within a heat shock protein. This host-
guest complex was able to generate H2 gas at the efficiency level of some 
naturally occurring hydrogenases.64 By preventing Pt from aggregating in 
solution by protecting it within a host cage protein, the nanoparticle was 
able to generate H2 gas by light driven photo-activation of a Ru complex. 
The Ru complex would transfer an electron to methyl viologen, which in 
turn donated the electron to the Pt nanoparticle to reduce protons to H2 gas. 
Methyl viologen degraded quickly in the solution due to exposure to Pt, 
however, and further improvements must be made. More importantly, this 
study demonstrated a step towards integration of inorganic nanoparticles 
with biological scaffolds for the purpose of catalytically generating a highly 
useful fuel substance.  
1.2.5. Novel Metal Centres  
Even before the exact mechanism of the ferroxidase centre was 
elucidated there had been experimentation to utilize the machinery of 
ferritins to introduce new metals into ferritin to form cores of defined and 
uniform size. The development of novel nanoparticles of defined size has 
revolved largely around the use of commercial horse spleen ferritin and 
some viral protein shells (capsids).65 There have been many different 
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approaches to the generation of nanoparticles, including utilizing the 
inherent ferroxidase centre66, by addition of hexacyanoferrate(III)67, or 
encapsulation of a metal of interest followed by the addition of an 
appropriate nucleating agent, wherein the protein cage acts as a physical 
enclosure to limit core growth.68-70 The types of metals and metal 
composites utilized are diverse in form, crystallinity, composition (Mn, Co, 
Cu, Ni, Cr, Pd, CdS, ZnSe, Fe2O3) and properties (magnetic, semiconductor, 
and fluorescence).65,68,69,71 The nanoparticles harvested from these protein 
cage systems are good examples of how ferritins, and indeed other cage 
systems, can aid in materials development. 
 
1.2.6. Cofactor Modification  
Protein cofactors provide an expanded range of functionalities that 
the 20 canonical amino acids cannot otherwise provide. Such cofactors 
include: NAD(P)H, flavins, metal atoms or clusters, pyridoxal phosphate 
(PLP), pterins, biotin, quinones, protoporphyrins, chlorins, and many others. 
A critical role of some cofactors is to handle the processing of electrons, 
either single electrons or pairs of electrons. Most notably are the flavin, 
metal centres or clusters, and protoporphyrin cofactors in their unique ability 
to handle single electron transfers. Most redox proteins, and electron 
shuttling proteins involve the use of one or multiples of these cofactors to 
transmit electrons. These classes of enzymes and proteins are of particular 
interest because of the ubiquity of the cofactors, the diversity of enzymes 
and protein functions, and their integration into devices. Each cofactor 
having its limitations and advantages that lend it to applications in the 
aforementioned areas. 
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1.2.6.1. Applications of Chlorin and Heme Modifications 
Separate from the class of flavins and NAD(P)H cofactors are the 
protoporphyrins, which are certainly one of the most diverse cofactors found in 
nature. An excellent publication on the aspects of heme and protoporphyrins in 
biology can be accessed for more in depth review.72 Diversity of functions 
include: catalysis, substrate transport (oxygen in hemoglobin), and electron 
relay. Such a seemingly large range of purposes from a single class of cofactor 
are possible through several points of variation. For instance, modulation of the 
redox properties of protoporphyrins can be accomplished by changes to the 
coordinating residues on the transition metal (Figure 1.3). Amino acid residues 
coordinating the metal in protoporphyrins can provide ligation of the metal in 
one or two positions. Some such known residues are His, His-His, His-Met, 
Cys, Met-Met, and Tyr-His.72 
As might be expected from the diversity of functions, the architecture of 
heme binding proteins is not conserved, and many structures exist. Hemoglobin, 
a text book example of molecule transport, uses a heme-b protoporphyrin and is 
coordinated by proximal His(F8). Pre-oxygen binding, the iron is 
pentacoordinated, which becomes hexacoordinated upon oxygen binding73. A 
distal His(E7) co-coordinates with the dioxygen molecule while it binds to the 
ferrous iron of heme-b (Figure 5). The iron atom must be ferrous to bind and 
transport oxygen, and the proximal His is essential in the mechanism and fine 
tuning of heme for this purpose.74  
His-His interactions can be seen with cytochrome c oxidase (Cox), which is 
a Cu-heme membrane protein involved in the reduction of molecular oxygen to 
water in the electron transport chain.75 Cox coordinates two heme-a cofactors, 
one with a bis-His coordination. This bis-His coordinated heme transports a 
total of four electrons and shuttles them to the second heme reaction centre to 
eventually reduce molecular oxygen76. Redox potentials associated with the 
heme-a cofactors have been reported to range between 260 mV and 340 mV, 
compared to the heme-b situated in hemoglobins which can have a redox 
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potential of -52 mV.77 This demonstrates how even though the same residues 
coordinate the heme group, modifications to the macrocycle and changes in the 
protein architecture can greatly modulate the heme redox potential. An example 
of Cys (thio/thiolate) coordination of heme cofactors can be seen in the enzymes 
termed cytochrome P450 (P450).78 This class of enzymes has great importance 
in the metabolism of fatty acids, steroids, and xenobiotics. The role of heme in 
P450 is to activate molecular oxygen at the heme iron to an iron-oxo 
intermediate, which is then primed to react with substrates.79 The thiol-ligated 
heme-b in P450s has a redox potential in the substrate free form of 
approximately -220 mV, which changes as substrates bind and the spin state of 
iron changes.80 Lastly, a bis-Met coordinated heme-b cofactor example can be 
seen in the Bfr class of proteins. As mentioned previously Bfr is a storage 
protein, used to maintain a repository of iron within cells. Although the function 
of heme had been debated, recent evidence has emerged supporting its role in 
triggering iron release from the cage interior, as outlined below. Bfr heme-b has 
been shown to interact with a Bfr-associating protein that derives electrons from 
ferredoxin, and was proposed to transfer electrons to the ferroxide centres inside 
the Bfr cage.81 The observed redox potentials in Bfr have been between -475 to 
-225 mV depending on whether the iron core is present or not82.  
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Figure 1.3: Some of the most common forms of heme in nature, and a chlorin.  Heme-b (A) is one of 
the common types of heme found in nature. The iron metal can be coordinated by two histidine 
residues (B), by single histidine residues, or by other amino acids like methionine, and cysteine. 
Variations of heme are seen in nature, such as heme-a (C), and heme-c (D). Variations of chlorin (E) 
can also be used to substitute heme in some proteins, for instance chlorin E6 (F) has been used to 
incorporate within bacterioferritin. 
C 
BA 
D 
E F 
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The propionate groups found on heme have a somewhat unexpected 
role, and are important in the handling of single electrons. P450s and 
peroxidases may delocalize single electrons to the carboxylate groups on the 
propionates, and may be somewhat involved in the transfer of electrons, as 
evidenced by crystallographic data showing interaction between peroxidase 
substrates and the propionate groups of its heme cofactor.83 If indeed the 
propionate groups are more critical for the function of heme containing proteins 
than previously thought, then surely the pKa of the carboxylate groups would be 
important. This very property has been observed in heme-containing proteins 
where changes to the propionate local environment, and thus the pKa, appeared 
to modulate the redox potential of the heme.84  For these reasons, and reasons 
discussed in previous paragraphs, hemes have been touted as one of the most 
versatile cofactors in biology, with a reported range of 800 mV in redox 
potential.85,86  
In addition to native heme diversity, investigation into the modification 
of heme and heme proteins has also become of interest for the biotechnological 
and bionanotechnological community. There is great interest in enzymes, 
specifically redox enzymes, in biotechnology for the production of chiral 
compounds, biofuels, and in the disposal of harmful waste compounds.87-90 
Protoporphyrin containing enzymes have been explored for these purposes to 
improve some industrial applications in synthesis and degradation. The major 
contender in this area is P450, with the notable addition of cellobiose 
dehydrogenases. P450s are primarily used for the production of new 
compounds, pharmaceuticals, optically pure molecules, and for 
bioremediation.91 Biofuel cells are more commonly mentioned with cellobiose 
dehydrogenases and glucose oxidase.89,90 By linking either direct or mediated 
electron transfer to an electrode from the cellobiose dehydrogenase, researchers 
have been able to generate electrical current.89 These literature examples show 
that distinct heme coordinating proteins can be used for the development of 
industrially relevant technologies. This means that understanding the modes of 
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electron transfer and how to modulate them will be essential for further 
development and understanding in this field.    
Research has also been reported on modification of the propionate 
groups as well as the macrocycle itself, as outlined below. Modification to the 
Macrocycle can alter the electrochemical properties of the heme, as seen with 
the differences between chlorins and protoporphyrins.92 Chlorins, generally, are 
easier to oxidize than protoporphyrins, and chlorins have been demonstrated to 
be exchanged with heme in heme proteins.93 Although the macrocycle is a 
powerful place to modulate these characteristics, macrocycle modification as it 
relates to replacement in heme proteins has been less explored in research.  
More interest has been paid to the exploration of the propionate groups 
on protoporphyrins and heme. Labelling of heme propionate groups usually 
follows a similar synthetic route, activating the carboxylic acid with a 
carbodiimide followed by the addition of a desired amine containing label. The 
Niemeyer group has labelled heme propionate with DNA for the purposes of 
directing horseradish peroxidase and myoglobin to surfaces containing the 
partner DNA strand (Figure 1.4).94-97 Heme was doubly labelled, and singly 
labelled with DNA oligonucleotides followed by evaluation of the enzymatic 
activity upon surface binding. Interestingly, the group also demonstrated 
selective labelling of individual propionate groups on a single heme through use 
of a glass support.98 They were capable of labelling a single heme with both a 
single stranded DNA oligomer and a photosensitive ruthenium complex. The 
ruthenium complex was photo-activatable and able to reduce the heme iron. The 
single stranded DNA was used to associate the heme to a surface presenting the 
complementary DNA strand. Similar to this type of reduction, another group 
has reported the attachment of the myoglobin heme to a CdTe quantum dot that 
could photo-reduce the heme through the photo-activation of the CdTe quantum 
dot.99 Using a thiol containing label, they were able to directly attach multiple 
myoglobin proteins to the CdTe quantum dot through the heme moiety. These 
examples show how heme proteins can be attached to surfaces and reduced 
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when coupled to photo-activatable groups. 
 
 
Figure 1.4: Examples of the modifications that have been made to the propionate groups of heme-b. 
Modifications to heme demonstrate how additional functionalities can be introduced to heme 
containing proteins (A). Through addition of a DNA oligomer researchers were able to attach 
myoglobin to a surface and label the second propionate group with a photo-activatable ruthenium 
complex (B).98 Heme has also been labelled directly to a CdTe QD, which was able to reduce the iron 
centre upon photo-activation (C).99  
Myoglobin and horseradish peroxidase have shown enhanced rates of 
reaction with the addition of N,N-Di(carboxylate)-1,3,5-Benzenetricaboxamide) 
derivatives to the heme propionate groups. Functionalization of the propionate 
groups with N,N-Di(carboxylate)-1,3,5-Benzenetricaboxamide was shown to 
enhance the rate of peroxidase activity of myoglobin towards 2-
methoxyphenol100. This increased activity could possibly be due to the aromatic 
benzene ring interacting with the phenol ring of the substrate. Similar work was 
performed that discovered increased thermo and solvent stability of myoglobin 
after heme modifications were made.101  
Biosensor development through direct electron transfer from heme 
proteins to electrodes is another possibility for heme proteins.102 Electron 
tunneling through proteins is very distance dependent, and proper positioning of 
the heme moiety is essential for efficient electron transfer in heme proteins. 
Orientation of heme in the heme protein at an electrode surface is important for 
A B 
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Ru 
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biosensors, and can be applied to most electrode modifications with heme 
containing electron transfer proteins. For example, heme has been attached to a 
titanium nano-rod through its propionate groups, which coordinated horseradish 
peroxidase for the purpose of developing a peroxide biosensor.103 The many 
examples of chlorin/protoporphyrin cofactor modification provide foundational 
evidence for the breadth of interest and application of a ubiquitous class of 
cofactors.  
1.2.7. Bioconjugates  
Bioconjugation is an essential component to many of the studies 
outlined in this chapter. Conjugation is required to specifically anchor guest 
molecules to the host cage proteins, and/or to provide affinity linkers between 
multiprotein complexes and various guests.  
1.2.7.1. Bioorthogonal Reactions 
Ideal reagents for covalent modification of proteins would have the 
following properties: solubility in water, selectivity to a particular functional 
group, reactivity producing high yields, and an ability to undergo reaction at 
physiological temperatures and pH. These requirements have spawned 
development of bioorthogonal and “click” chemistry reactions. The first 
bioorthogonal reaction was derived from the Staudinger reduction reaction 
(Table 1). A phosphine reacts with azides, a functional group not found in 
proteins, and is thus very selective and has minimal side reactions. Subsequent 
modification of this reaction, termed the Staudinger ligation, allowed for 
chemical attachment of functionalities to the azide group (Table 1).104 Both 
reactions require two components: an organophosphine and an organoazide.105 
These functional groups are compatible with biological systems such as proteins 
and cells. The reagents can be made water soluble, and the ligation reaction can 
proceed under physiological pH and temperature. The difference between the 
reduction and the ligation reactions is that the ligation reaction uses a 
diphenylphosphine-containing arene with an ester ortho to the phosphine 
moiety. This arrangement allows for the formation of an intermediate aza-ylide 
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that rearranges to form a stable amide. The phosphorus atom remains in the 
product.105 This reaction is possible in vivo, but problems arise with the labile 
phosphine reagent and the length of time it takes to react. However, this is not 
as much of an issue for in vitro protein labelling. A related ligation strategy has 
arisen from a reaction based on a copper catalyzed azide-acetylene 
cycloaddition developed by Huisgen (Table 1).106 Although the Cu(I) catalyzed 
reaction is still applicable for in vitro synthesis the Cu(I) catalyst is somewhat 
toxic to cells. Formation of the disubstituted 1,2,3-triazole is found in both the 
Cu-catalyzed azide-alkyne cycloaddition and the cyclooctyne azide addition, a 
reaction developed to eliminate the need for copper catalysis for the 
cyscloaddition reaction (Table 1).  
Diels-Alder-based cycloaddition reactions have recently been developed 
to be water soluble and capable of use in bioconjugation reactions. Attachment 
of a diene to a protein followed by cycloaddition of a derivatized maleimide can 
allow for attachment of small molecules such as fluorophores or peptides (Table 
1).107 All of these reactions have been developed for use under aqueous 
conditions, but most require functionality not found in proteins (azides, alkynes, 
and aldehydes for example). There are several methods available to introduce 
these unique functionalities into proteins, or to take advantage of the functional 
groups already present in the protein.   
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Table 1: A summary of the bioorthogonal reactions discussed with the associated chemical 
mechanisms  
Reaction Mechanism  
Staudinger 
reduction108 
 
Staudinger 
ligation109 
 
Cyclooctyne 
azide addition109 
                  
Diels-Alder 
cycloaddition107 
 
1.2.7.2. Natural Amino Acid Modifications 
In order to accomplish the above bioorthogonal ligation reactions with 
proteins it is necessary to introduce the appropriate chemical functionality into 
the protein scaffold. There are solutions to incorporate these functionalities, as 
well as other functionalities, into proteins: site directed mutations introducing 
natural but reactive amino acids, unnatural amino acid incorporation, 
recombinant genetic fusion peptides, and enzymatic modifications. Naturally 
reactive amino acids, either native to the sequence or generated through 
recombinant point mutations, have the ability to decorate a protein with unique 
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functionalities. The most common amino acids used for these types of reactions 
are cysteine (Cys), lysine (Lys), tyrosine (Tyr), glutamate (Glu), and aspartate 
(Asp). Cys is the most frequently utilized for these purposes.  
Cys is unique because of its reactive thiol, and its generally low 
sequence abundance.  There have been many studies that have introduced a Cys 
residue into a protein sequence for downstream chemical modification.110 Such 
modifications can be between the very reactive cysteine thiol with maleimide 
analogs derivatized with a functionality of interest (Figure 1.5).31 The 
maleimide reacts with the thiol of Cys to produce a stable carbon thioether 
bond.111 Lys residues in proteins can also be modified under basic conditions.112 
The ε amino group on Lys can react with an activated ester to form an amide 
bond, or can react with isothiocyanate.113  
 
Figure 1.5: An example of possible cysteine labelling with maleimide on the surface of Bfr. The R 
group on maleimide could be fluorescein, nanogold, or biotin for example114. Images generated using 
Pymol (PDB ID: 1BFR), and ChemSketch 
Tyr can be conjugated to diazonium salts, which attack ortho to the 
phenolic group on Tyr to form a disubstituted hydrazine.115 Tyr can also be 
modified by the π-allyl species activated with Pd-based catalysts to form an 
ether linkage with the para hydroxyl.116 Glu and Asp can both be modified with 
N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) to activate the 
carboxylic acid to react with an amine to form an amide bond; an interesting 
application used EDC to attach alkylamines to ferritin to make ferritin 
completely soluble in dichloromethane.117  
+ 
1:4 DMSO:Buffer 
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At times, modification of natural amino acids does not suit the 
application of the particular system due to cross reactivity or multiple activated 
residues, and so other methods of conjugation have been developed.  
1.2.7.3. Unnatural Amino Acid Substitution 
A number of synthetic unnatural amino acid analogs that utilize the 
native aminoacyl tRNA synthetase (aaRS)/tRNA pair can be incorporated in a 
residue-specific manner into proteins. There are a select number of unnatural 
amino acids (Met analogs have been popular118) that can be added to the growth 
media of auxotrophic bacterial strains and compete well with the natural amino 
acids for incorporation into a protein. The use of auxotrophic bacterial strains 
allows for suppression of synthesis of the particular natural amino acid and 
improves analog incorporation levels. Proteins have been labeled successfully in 
this way, and it provides a useful alternative to the naturally reactive amino 
acids by directly introducing functionalities capable of being further modified, 
such as the alkyne and azide chemical moieties.119 
1.2.7.4. Enzymatic Conjugation  
Beyond the scope of more traditional chemical modifications are the 
techniques of enzymatic modification. The advantage with many enzymes is 
that they often require a recognition sequence, which makes them much more 
specific to a particular location. These enzymes either recognize sequence 
motifs or residues to modify a protein by adding lipid chains, sugar units, and 
other peptides.  
One such enzyme, transglutaminase, will catalyze the hydrolysis of 
glutamine side chains and, in the presence of suitable amine donors, transfer 
amines onto the side chain of the glutaminyl residue (Figure 1.6). Amide 
linkages are thus generated under mild conditions, with high specificity, 
between the γ-carboxamide of Gln and with low specificity from the ε nitrogen 
of Lys. The lowered specificity to the Lys residue has allowed for the 
modification of Gln with functionalized Lys residues.120   
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Figure 1.6: The enzymatic mechanism for transglutaminase showing a Gln residue (R) as an acyl 
donor to acylate the enzyme. The acyl acceptor (R1) enters the active site and becomes acylated by 
the enzyme, which conjugates the donor to the acceptor and generates an isopeptide. 
1.2.7.5. Non-covalent Affinity Interactions 
Non-covalent interactions are a very important aspect in biological 
systems, often permitting more dynamic interactions that can be controlled. 
There are many biological non-covalent examples, such as coiled-coil helix 
interactions, DNA cognate pairs, metal coordination, aptamers, and 
hydrophobic and electrostatic sticky patches.121-124 Non-native affinity 
interactions can be generated by techniques like phage display, which has been 
a tremendous source of short peptide sequences with high affinity for protein, 
organic, and inorganic substrates.125 The addition of these affinity ligands can 
often be through established molecular genetic techniques at the C or N 
terminus of proteins, or as an added loop to proteins with relative ease.126  
1.3. The Ferritin Superfamily  
1.3.1. Sequence Identity 
The research in our laboratory has involved the exploration of the 
multiprotein complex bacterioferritin (Bfr) from Escherichia coli (E. coli) as a 
cage protein that is potentially useful in novel nanomaterials development. Bfr 
is a spherical cage protein complex composed of 24 identical protomers. Its 
primary function is to oxidize FeII and store it as solid FeIII (Figure 1.7).127 
Ferritins essentially act as a primitive type of organelle that stores excess iron. 
Bfr is a member of the ferritin family of proteins, which include eukaryotic 
ferritin, bacterioferritin, and Dps (DNA-binding protein from starved cells).128 
The amino acid sequence identity between Bfr and other ferritins is less than 
20%, but despite the low sequence identity there is a high degree of structural 
conservation.129 Since the sole function of ferritins is to deposit oxidized iron as 
a core, the residues that participate in iron oxidation (called the ferroxidase 
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centre) are highly conserved in each ferritin subfamily.128 The ferroxidase centre 
will be discussed below.  
 
 
Figure 1.7: Overview of the structural data on Bfr and the ferroxidase centre found on the interior 
surface of each protomer. The four α-helical bundle of Bfr with the helices labelled is the base 
structural unit (A). The heme group is coordinated by two Met52 residues (B). The functional unit of 
Bfr is the dimer and it contains a maximum of a single heme, and two ferroxidase centres (C). The 
ferroxidase centre coordinates two iron atoms with 4 Glu, and 2 His residues, and allows for the 
reduction of molecular oxygen into water to facilitate the deposition of an iron core from the inner 
surface site (D). Images generated using Pymol (PDB ID: 1BFR) and Microsoft Powerpoint.   
1.3.2. Ferroxidase Center  
Ferritins function as storage molecules for iron in the cells of the 
majority of species on Earth because of the essential need for iron in cellular 
processes, such as in the electron transport chain. Due to the Fenton reaction 
and the production of harmful hydroxyl radicals, soluble iron levels need to be 
controlled.130 All ferritins contain a dinuclear iron (ferroxidase) center found in 
intra-subunits for ferritins and Bfr, or formed by inter-subunit interactions for 
Dps.131,132 The ferroxidase centre in Bfr is composed of two iron binding sites 
per subunit, each composed of four glutamate residues (18, 51, 94, 127) two of 
A 
B 
C D 
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which bridge the two Fe2+ (51, 127), and two histidine residues (54, 130) 
(Figure 1.7).133 This centre functions to bind incoming Fe2+ entering through 
pores in the protein shell. Different from the ferritins, bacterioferritin contains a 
maximum of twelve heme groups each sandwiched between two adjacent 
subunits.  The role of heme was, until recently, unknown and few kinetic studies 
had been performed to better characterize its function. Now, heme has been 
shown to be important in core removal, and kinetically important for core 
formation as well.134 
1.3.3. Structural Composition 
Ferritin, Bfr, and Dps of the ferritin superfamily have highly conserved 
tertiary structures, and for ferritin and Bfr, quaternary structures. Ferritins and 
Bfr are discussed in two contexts: one is with concern of the 24-mer intact 
quaternary structure (α24), and the other is the dimer (α2), which is considered 
the functional unit of the ferroxidase center. The amino acid length of each E. 
coli Bfr protomer is 158 amino acids, with a molecular weight (MW) of 18.5 
kDa, and the multiprotein complex has a MW of 443.9 kDa. For all three 
subfamily members the protomer consists of a square, left-handed, four α-
helical bundle, and in the case of ferritin and Bfr a fifth C-terminal helix is 
present. The fifth helix in ferritin and Bfr sits almost perpendicular to the plain 
of the helical bundle.135The helices are labeled as A through to E, AB being 
antiparallel to CD with one large loop connecting helix B to C. Bfr and ferritins 
form a 24-mer dodecahedron cluster with the same overall symmetry as a cube 
(octahedral) with 2-, 3-, and 4-fold symmetry (Figure 1.7). Pores are found at 
the 3- and 4-fold symmetry axes and the B-channel at the interface between 
dimers to facilitate iron movement into and out of the interior space (Figure 
1.7).136 The Bfr complex is approximately 12 nm in outer diameter, and the 
interior cavity is approximately 8 nm in diameter, with an interior volume of 
2144 nm3. The N-termini are situated such that they face the exterior of the 
protein cage, and the C-termini are situated to face the interior of the cage.  
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Each protomer is involved in binding interactions at each of its four 
interfaces.  Structural experiments have been performed to elucidate the factors 
contributing to complex formation focusing on the role of the E helix, and 
improvements to complex stability. Since Dps lacks the E helix, a study was 
reported which attempted to evaluate the importance of the E-helix to the 
structure of these family members. A swapping experiment was performed 
between Bfr and Dps. Analysis of the data indicated that the E helix is essential 
for Bfr complex stability, and that it may be important in differentiating the 12-
mer and 24-mer states.137 There has also been an investigation to improve the 
stability of the Bfr complex by mutagenizing Asn residues at one interfacial 
water pocket. Removal of this water pocket with either introduction of Phe or 
Trp resulted in temperature stability increases for the protein of up to 20°C, and 
stability increases in guanidinium HCl dependent unfolding by approximately 
1M.138 The temperature stability of Bfr has been determined to be stable up to 
approximately 85°C.  
One of the major distinctions between Bfr and other ferritin family 
proteins is the presence of 12 heme cofactors. A binding pocket exists between 
the dimer interface, where a methionine from each protomer coordinates the 
heme iron. The propionate groups of heme face the interior of the protein cage 
and thus there are 24 propionate groups on the interior. Based on the crystal 
structure of E. coli Bfr the propionate groups associate electrostatically with the 
side chain amine on a Lys residue, but no function has been assigned to this 
possible interaction. Heme, until recently, was debated as to its role in ferric 
iron core formation. Heme has been shown to not be absolutely required for iron 
core formation or for the liberation of free iron from the core. Since eukaryote 
ferritin functions without a heme cofactor, it was hypothesized that heme might 
have been a vestigial cofactor, and not important in iron homeostasis. In 
addition, heme was demonstrated to not be essential for proper structural 
formation either. These facts appeared to demote heme to a functionless 
cofactor. In more recent papers heme has been assigned a role in the increased 
rates of iron core formation in Bfr.139 In addition to kinetic analysis, structural 
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data from Pseudomonas aeruginosa revealed a ferredoxin accessory protein 
involved in electron transfer through the heme moiety to the iron core to free 
iron.81 It appears that heme is more likely central in the regulation of iron 
release and formation of iron cores.    
1.4. Motivations for Pursuing Protein Based Nano-devices 
The purpose of the experiments presented in this thesis are to further 
develop the field of self-assembling cage proteins as novel biomolecular 
platforms for control of host-guest interactions, and for development of 
advanced nanomaterials. Proteins are soft materials that form complex 
structures and geometric arrangements through genetic coding. Protein 
biochemistry has advanced such that there exists an immense repertoire of 
methodologies for monitoring and modifying these systems. Through structural 
data, genetic information, chemical bioconjugation, and detailed study of the 
function of proteins, the ability to repurpose or exploit functionalities has seen a 
growing number of examples in the literature. The reasons why protein cages 
have seen growing interest can be attributed to the nanometer size of the 
complexes. This scale remains difficult to control and generate new materials 
within. By using the already available proteins, design of new materials or 
devices at the nanometer scale is possible because of the exquisite 
controllability of protein scaffolds. Examples exist of the development of 
delivery vehicles, imaging agents, nanomaterial components, ferries/shuttles, 
and nano-sized reactors. The continued development of this field is important to 
expand leading-edge applications.  
Investigation of Bfr entails two main approaches, one is to probe the 
limits of its use as a platform for encapsulation (host-guest interactions), and the 
second is to modify the native heme cofactor to provide an additional capability 
for encapsulation control. By exploring Bfr as a highly controllable 
nanomaterial one can envisage its usage in the fields of drug delivery and 
nanomaterial science, as has been recently demonstrated for other cage protein 
systems. Bfr has been chosen because of its more simple quaternary structure 
32 
 
(identical 24 protomers) and the presence of heme, a potentially novel and 
controllable element to this multiprotein system.140
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2. Chapter 2: Encapsulation Studies  
2.1. Introduction  
This chapter will outline and discuss the methods for preparation and 
purification of bacterioferritin (Bfr) and Bfr mutants used in this research, and 
the encapsulation within Bfr of Streptavidin labelled with fluorescein (SF) and 
1.8 nm and 5 nm gold nanoparticles (GNP). Some investigation on the nature of 
the assembly of 24mer Bfr with respect to the presence of heme will be 
discussed at the end of this chapter. 
Four Bfr variants will be explored in this chapter: wild type (WT) Bfr, 
Hexahistidine tagged (His6-tag) Bfr, Methionine-less (BfrM), and S-tagged (S-
Bfr). The WT and His6-tag Bfr were both used for encapsulation studies. The 
His6-tag Bfr contained a hexahistidine tag, which was genetically engineered 
onto the C-terminus of Bfr, designed by Dr. Uthaiwan Suttisansanee.141 The C-
termini of Bfr face the interior of the 24mer, and thus could act as a specific 
affinity label for encapsulating guest molecules decorated with nitrilotriacetic 
acid (NTA) functionalities (Figure 2.1). This non-covalent interaction has a Kd 
as low as 10 µM, which makes NTA-histidine interactions highly specific.142 
Previous work by Dr. Uthaiwan Suttisansanee.141 had explored the 
encapsulation of a small molecular dye with an NTA functionality, ProQ® 
sapphire 365 oligohistidine stain. The dye was shown to be encapsulated, and 
some of the research discussed in this chapter was a continuation of this 
previous work.  
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Figure 2.1: A nitrilotriacetic acid (NTA) functionality coordinating a nickel atom (red) with two 
histidine residues. This affinity interaction was utilized for encapsulation of two large guest 
molecules within Bfr.    
The main topics of this chapter revolve around encapsulation of non-
native guest molecules within Bfr. In addition to this main theme, auxiliary 
projects were pursued to develop Bfr as a bionanomaterial. One such project 
was the generation of a methionine-less mutant construct, BfrM. BfrM had five 
of the seven methionines mutated to lysine. The two methionine residues left 
were the initiator methionine, and the heme coordinating methionine M52. This 
construct required that a total of five mutations be made: M31L, M86L, M119L, 
M120L, and M144L. The molecular weight of BfrM was calculated as 19470 
Da; higher than WT Bfr molecular weight because it also contained a 
hexahistidine tag on the C-terminus. This construct was made for the purpose of 
introducing unnatural methionine analogs into Bfr. With only the heme iron 
coordinating methionine remaining, methionine substitutions could be made to 
modulate heme electrochemistry. By modulating the electronic environment 
around the heme iron with methionine analogs the heme redox potential may be 
fine-tuned to alternative values. This type of electrochemical modification was 
performed in a previous study using methionine analogs to modulate the redox 
potential of a Cu2+ metal centre in an azurin protein.143 
 The second construct made was S-Bfr, which was an N-terminal 
extension of His6-tag Bfr. The N-terminus can be viewed in crystal structures as 
lying on the exterior face of the 24mer Bfr structure.144 The S-tag is derived 
from RNase A, which is composed of S-protein and S-peptide, both of which 
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are necessary for the function of RNase A.145 Residues 1-15 of the S-peptide 
have been determined as the minimum length necessary for function of RNase 
A; these 15 residues are the S-tag. The S-tag has been shown to not interfere 
with folding of host protein, and the dissociation constant between S-tag and 
protein-S can be regulated by mutagenizing the S-tag at specific locations.145,146 
In addition to this feature, which could be of future benefit to affinity 
purification studies, by adding the S-tag to the N-terminus it was hypothesized 
that the Gln on the S-tag would be more exposed than native Gln residues, and 
better suited for labelling by a transglutaminase. Transglutaminases form an 
epsilon-(gamma-glutamyl)-lysine cross linkage through proteins, and are 
regularly used in the food industry as a crosslinking agent in meat processing.147 
It has also been demonstrated that transglutaminase can label Gln residues with 
unnatural donor molecules modified with other chemical functionalities.148,149 It 
had previously been shown that addition of an S-tag to a protein could improve 
cross linking by microbial transglutaminase (MTG) from Streptomyces 
mobaraensis.150 S-tag contains both lysine and glutamine, the native substrates 
for transglutaminases, which afforded the opportunity to use both of these 
amino acids as separate, and specific labelling points on the surface of Bfr. This 
strategy will be further described in a chapter 4. 
The encapsulation studies explored two types of guest molecules: SF, 
and two sizes of GNPs. SF was a commercially available fluorescently labelled 
streptavidin (Appendix  2), which is a tetrameric protein of the avidin family of 
proteins taken from the bacterium Streptomyces avidinii.151 Streptavidin was 
chosen as a guest protein to probe the capabilities of Bfr to encapsulate large 
multimeric proteins, and to develop the methodologies to encapsulate complex 
biological guests. Streptavidin has an approximate size of 5-6 nm 152, which is 
large when compared to the 8 nm interior diameter of WT Bfr.  Streptavidin has 
one of the highest known non-covalent association constants with its native 
ligand, biotin, Kd of 10-14 M.153 Streptavidin is also a well-studied protein in 
molecular biology and in biotechnology, and was an ideal choice as a biological 
guest. A derivatized biotin was used in this research with an NTA functionality 
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synthesized onto the carboxylic acid on biotin. Thus, biotin-XNTA was the 
mediator between the high affinity interaction with streptavidin and the NTA 
metal dependant interaction with the hexahistidine tag found on Bfr. Three 
methods would be utilized to confirm the encapsulation of the SF guest within 
the host Bfr: chromatography, fluorescence quenching, and transmission 
electron microscopy (TEM).  
 Fluorescence quenching was used to confirm encapsulation by 
determining whether or not the fluorophore on streptavidin was protected by the 
protein shell of the host Bfr. This would be accomplished by titrating in a 
quenching molecule to the free and encapsulated SF and monitoring the change 
in fluorescence. This methodology was not unlike other experiments that have 
monitored tryptophan exposure in proteins with quenching.154  
 In addition to fluorescence measurements, TEM was pursued to 
characterize encapsulated SF. The methodology employed was negative staining 
of the samples in a heavy atom stain.155 The negative stain does not specifically 
associate with proteins, it merely creates a layer in which protein can embed 
itself. Some of the stain is displaced by the protein, which generates contrast, 
and thus features can be distinguished. As is known of the ferritin family of 
proteins, the structures contain pores that are requisite for their native function 
as iron storage units. The pores are large enough to allow the passage of atoms 
and small molecules to the interior, and by the same means atomic stains may 
also pass to the interior volume of Bfr.156 From this, it was hypothesized that 
determining the presence of encapsulated proteins within Bfr could be done 
with approaches utilizing negatively stained TEM. If there was a guest 
consisting of light atoms in the interior of Bfr it would exclude stain from the 
interior void, and this absence of stain could be visualized. TEM would be used 
for the determination of encapsulated GNP as well. Encapsulated GNP would 
be visualized clearly with TEM since the contrast between the highly electron 
dense GNP and the less electron dense protein would be high. Since the GNP 
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was not fluorescent, this would be a highly revealing method to verify 
encapsulation of GNP within Bfr other than chromatography.  
 Nanoparticles have been gaining interest in many fields. There has been 
particular interest in GNPs for their use in nanotechnology because of their 
biocompatibility, localized surface plasmon resonance properties, and optical 
properties.157,158 Not only GNPs, but other nanoparticles have very interesting 
optical and catalytic properties that may be utilized in the development of 
optical probes or nano-reactors. By providing a unique environment for these 
nanoparticles within protein shells, like Bfr, they are protected from 
environmental contaminants and reaction, and the internal environment can be 
specifically controlled while the exterior of the Bfr host could be modified to 
direct this type of probe to various cellular or synthetic surfaces. By studying 
GNPs they may serve as a benchmark for the encapsulation of other 
nanoparticles, such as quantum dots.  
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 In addition to the development of Bfr as a nano-platform, insight into the 
self-assembly characteristics of Bfr were explored. The mechanism of assembly 
from subunits to a fully formed 24mer in ferritins is still not a completely 
understood process. There are two clear states known, the dimer and the 24mer 
state, but intermediates between these two are uncharacterized.137,159 Some 
differential scanning calorimetry studies have been performed on ferritins, but 
only on individual units rather than full complexes.160 There seems to be an 
inherent equilibrium between the dimer and 24mer state, which is observed as 
two well separated protein peaks when pure ferritin is run on size exclusion 
columns. Some researchers have explored directed mutagenesis with Bfr to 
define important interfacial residues and improve resistance to temperature and 
pH changes.137,161,162 These studies have focused largely on the role of 
interfacial residues and the e helix, but not of the role of heme in Bfr. 
Understanding the phenomenon of self-assembly is of importance because it 
will allow researchers to control the states that multimeric proteins occupy. For 
instance, ferritin has an equilibrium between dimer and 24mer. If one could 
force the equilibrium towards dimer formation, when desired, and then trigger 
complex formation then this would lend much more control to the system. Such 
a technique would be of great interest for studies of encapsulation, since they 
would no longer require harsh chemical or physical disruption to modulate the 
presence of certain assembly states.     
2.2. Materials and Methods 
2.2.1. Materials 
Streptavidin FITC (Life Technologies, Frederick, MD, USA), dabsyl 
chloride (Sigma-Aldrich, Bellefonte, Pennsylvania, USA), Biotin-X NTA 
(AnaSpec, Fermont, CA, USA) Black Hole Quencher® 10 (BHQ®-10; 
Biosearch Technologies, Novato, CA, USA), and Ni-NTA-NanogoldTM 
(Nanoprobes, Yaphank, NY, USA) used for encapsulation studies. Formvar-
Carbon 400 mesh, Cu Grids (Canemco-Marivac, Gore, QC, Canada), Molybdic 
acid ((NH4)6Mo7O24) (Sigma-Aldrich, Saint Louis, MO, USA), Phosphotungstic 
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acid (H3PW12O40) (Sigma-Aldrich, Saint Louis, MO, USA), and Uranyl acetate 
(UO2(CH3COO)2) (generously donated by Dale Weber of the department of 
Biology in the University of Waterloo) for TEM. Plasmids (Novogen, 
Mississauga, ON, Canada), and primers (Sigma-Genosys, Oakville, ON, 
Canada) were used for genetic work. All buffers were made with Milli-QTM 
water with a resistivity of 18 MΩ·cm and filtered through a membrane with a 
0.45 µm cut-off.   
2.2.2. Safety Statement 
All bacterial samples were handled in accordance to level 1 safety 
laboratory facilities. After use, all bacterial samples were bleached or 
autoclaved to sterilize the media before disposal. All uranyl acetate used with 
TEM was disposed of properly through the waste management facility. The 
safety of the experimenters and others was of the utmost importance throughout 
experimentation.  
2.2.3. Purification of Bfr and Bfr mutants 
The Bfr genes on selectively inducible vectors were transformed into 
and overexpressed in E. coli BL21 cells using standard expression techniques. 
In brief, a pET-22b vector was used to express WT and His6-tag Bfr, whereas a 
pET-29b vector was used for the S-Bfr expression, and a pGS-21a vector for 
BfrM expression. All vectors contained the lac operon, which was used to 
induce expression of Bfr with the addition of 1 M isopropyl β-D-1-
thiogalactopyranoside (IPTG) to a final concentration of 1 mM in 1.5 L of 
media while cells were in mid-log phase growth. Cells were harvested using a 
Beckmann JA10 centrifuge at 5000 rpm for 20 minutes. Pellets were collected 
and re-suspended in 20 ml of 50 mM Tris 100 mM NaCl buffer at pH 8.0. The 
re-suspended cells were homogenized on an Avestin Emulsiflex-C5 
(Mannheim, Germany) at a pressure of 17000 psi, and then centrifuged at 15000 
rpm in a Beckmann JA25.5 rotor for 20 minutes. Supernatant was collected and 
heat shocked at 70 °C for 10 minutes and then left to cool to room temperature. 
This was again centrifuged using a Beckmann JA25.5 rotor at 15000 rpm for 20 
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minutes. The supernatant was collected to be further purified using 
chromatographic techniques.  
 Purification of WT Bfr was performed using anion exchange and size 
exclusion resins. A Bio-Rad Uno Q1TM anion exchange resin, which had a resin 
volume of 1.3 ml, and a binding capacity of 180 mg/ml. The column was run 
with an equilibration buffer of 50 mM Tris, 100 mM NaCl at pH 8.0, and 
elution buffer of 50 mM Tris, 2M NaCl at pH 8.0. Fractions were analyzed for 
the presence of WT Bfr using a 15% SDS-PAGE gel, and fractions containing 
WT Bfr were pooled and concentrated using an Amicon concentrator with a 10 
kDa cut off. WT Bfr was then run on a GE SephacrylTM S-400HR size 
exclusion column with a resin bed of 402.2 ml. The flow rate was 0.5 ml/min 
and fractions were collected every minute. Fractions were analyzed using a 15% 
SDS-PAGE gel and fractions containing pure WT-Bfr were pooled and 
concentrated, as before. If the ratio of 260/280 was above 1.0 then a Bio-Rad 
type II ceramic hydroxyapatite® column was used to separate contaminating 
DNA from WT Bfr. The equilibration buffer used was 10 mM potassium 
phosphate dibasic buffer at pH 6.8, and 400 mM potassium phosphate dibasic 
buffer at pH 6.8 was used as an elution buffer. Fractions were examined on a 
15% SDS-PAGE gel, and fractions containing pure WT Bfr lacking DNA were 
pooled, as before. WT Bfr was analyzed with MS. An electrospray ionization 
quadrupole time of flight mass spectrometer (Waters, Micromass Masslynx) 
was used to analyze the mass of protein samples.  
 His6-tag Bfr, BfrM, and S-Bfr all contained his6-tags, and were all 
purified using the same methods. His6-tag containing Bfr was purified using a 1 
ml GE HisTrapTM affinity column. Equilibration and elution buffers were 50 
mM Tris, 100mM NaCl, and 20 mM imidazole at pH 8.0, and 50 mM Tris, 
100mM NaCl, and 300 mM imidazole at pH 8.0, respectively. Elute was 
analyzed on 15% SDS-PAGE gels. Fractions were pooled and concentrated on 
an Amicon with a MW cut-off of 10 kDa. His6-tag containing Bfr were 
confirmed by MS, as before.  
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 His6-tag and WT Bfr were reconstituted fully with heme. The insertion 
method was followed from previous reporting on heme reconstitution into 
Bfr163. Hemin was suspended in a solution of 0.1 M NaOH to make a 10 mM 
solution of hemin. This was diluted with 0.2 M MES buffer at pH 6.5 to a final 
concentration of 1.5 mM hemin. This solution was then added to Bfr in excess 
of two equivalents at 80 °C in 0.2 M MES, 1M NaCl buffer at pH 6.5 for 10 
minutes, and then left to cool to 23°C. Bfr was run on a GE SephadexTM G-25 
Fine desalting column with 50 mM Tris, 100 mM NaCl buffer at pH 8.0 to 
remove free hemin and MES buffer.  
2.2.4. Encapsulation of SF and GNP  
 A molar equivalent of SF (0.1 mg, 1.89x10-9 mol) was pre-incubated 
with biotin-XNTA (0.021mg, 2.93x10-8 mol, 8.0 equiv.) and nickel sulfate 
(4.5x10-6g, 2.93x10-8 mol, 8.0 equiv.) in 50 mM Tris, 100 mM NaCl buffer at 
pH 8.0 for 10 min at 23 °C. SF pre-incubated with biotin-XNTA and nickel 
sulfate was added to Bfr (1.89x10-9 mol, 1.0 equiv.) in 8 M GndHCl buffered 
with 50 mM Tris, 100 mM NaCl at pH 8.0 for 90 minutes at 5 °C. This was then 
dialyzed against 4 L of 50 mM Tris 100 mM NaCl buffer at pH 8.0 for 24 
hours. The sample was concentrated with a Pall Nanosep® spin column with a 
10 kDa cut off to a volume of 0.5-1 ml. Free SF was separated from 
encapsulated SF using a GE SephacrylTM S-300HR resin, void volume of 99.05 
ml, running with a flow rate of 0.5 ml/min collecting fraction volumes of 0.5 
ml. The running buffer was the same as the dialysis buffer. The first peak was 
collected and concentrated to 1 ml as before.    
 The 1.8 nm GNP (1.0x10-9 mol) was pre-mixed with nickel sulfate 
(1.0x10-7 mol, 100 equiv.) in 50 mM Tris, 100 mM NaCl buffer at pH 8.0 for 10 
minutes at 23 °C. Pre-incubated 1.8 nm GNP mixed with nickel sulfate was 
stirred in with Bfr (0.5 mg, 1.0x10-9 mol, 1 equiv.) in 8 M GndHCl for 90 
minutes and then dialyzed into 4 L of 50 mM Tris, 100 mM NaCl buffer at pH 
8.0 for 24 hours at 5 °C. This was purified in the same manner as described for 
encapsulated SF. 
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 The 5 nm GNP (1.0x10-10 mol) was pre-incubated with nickel sulfate 
(2.0x10-8 mol, 200 equiv.) in 50 mM Tris, 100 mM NaCl buffer at pH 8.0 for 10 
minutes at 23 °C. Pre-incubated 5 nm GNP was mixed with Bfr (0.1 mg, 2x10-10 
mol, 2 equiv.) at 70 °C for 90 minutes. After 90 minutes, the solution was left to 
cool to 23 °C. The sample was purified in the same manner as described for 
encapsulated SF.  
2.2.5. Quenching Experiments  
 Quenching agents were iodide, Dabsyl-glutamate, and BHQ®-10. 
Dabsyl-glutamate was prepared from Dabsyl-Cl following a previously reported 
procedure164. Syntheis was monitored by MS (Appendix  1). The stock solutions 
of iodide, Dabsyl-glutamate, and BHQ®-10 utilized were 0.1 M, 0.27 mM, and 
0.4 mM, respectively.  Each of these quenchers was titrated into a small volume 
cuvette (Hellma 45 μl) with 0.3 cm path length in one or two microliter volume 
increments. After addition of the quencher, the solution was vigorously mixed 
to ensure homogenous distribution of quencher. The emission scan was 
recorded over a range of 500-550 nm with a fixed excitation wavelength of 495 
nm. Slit widths for incoming and emission light were set to 1 mm. All 
fluorescence quenching experiments were performed on a PTI fluorimeter A-
1010B. Additional components attached were a LPS-220B lamp power supply, 
a SC-500 shutter control, MD-5020 motor driver, and 814 photomultiplier 
detection system using a maximum excitation wavelength determined from the 
excitation spectrum.  
2.2.6. TEM Preparation and Imaging 
Transmission electron microscopy was performed on a CM10 Philips 
microscope modified with an Advanced Microscopy Techniques image 
capturing CCD camera. The accelerating potential was set to 100 keV for 
imaging in bright field mode. Preparation for TEM imaging for both 
encapsulated SF and GNP was performed using 400 mesh copper grids with a 
carbon-formvar coating. Two negative stains were used to generate the contrast 
needed to visualize protein: Molybdic acid ((NH4)6Mo7O24), and Uranyl acetate 
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(UO2(CH3COO)2).  Molybdic acid, uranyl acetate, and phosphotungstic acid 
(H3PW12O40) stains were prepared and used as both 1.0 % and 0.5 % 
solutions.155,165 Encapsulated Bfr samples were prepared to a concentration of 
approximately 0.1 mg/ml, and buffered exchanged into water using a spin 
column to remove unwanted salts. Grids were prepared by placing a 20 μl 
sample droplet, two 20 μl droplets of water and one droplet of stain on 
Parafilm®. Using ultra-fine tweezers, the grid was placed on top of the sample 
droplet for one minute. The grid was then removed, dabbed with a piece of 
Whatmann No 1 paper such that almost all of the liquid was removed except for 
a thin glassy layer of solution coating the grid. This was then washed by placing 
in two the two subsequent water droplets as in the previous step without the 
minute wait time. The final step was to dip the grid onto the stain solution and 
then dab away excess stain until a thin glassy layer of solution was left on the 
grid. This was left, covered, at room temperature to dry for 24 hours. 
2.2.7. MS Preparation and Operation 
All protein samples were buffer exchanged for water using Pall 
Nanosep® 10 kDa cut-off spin columns and then diluted to a final concentration 
of 1-5 µM in a 50 µl solution of 1:1 water:MeCN with 0.2% formic acid. 
Protein samples were run on a Waters Micromass MassLynx nanospray 
electrospray ionization quadrupole time of flight (ESI-QToF) mass 
spectrometer. Spectrum was collected between 100-2500 m/z, and the protein 
mass was deconvoluted using the supplied MaxEnt-1 MassLynx software. 
Native MS was attempted with protein suspended in 20 mM ammonium acetate 
pH 7.0, as previously reported.166,167 The collision energy and cone voltage were 
lowered to 10 eV and 2.0 V, and sample in ammonium acetate was directly 
injected into the mass spectrometer. A Thermo Scientific Q-ExactiveTM was 
used when the QToF was down. The samples were prepared in the same 
fashion, except re-suspended in 1:1 water:MeOH with 0.1% formic acid. 
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2.2.8. EMAN2 Image Processing 
Images were imported into the EMAN2 workflow GUI to appropriately 
prepare particles for analysis168. The methodology used was based on the 
several tutorials on the EMAN2 wiki, but the general procedure will be outlined 
here. In general, EMAN2 was used in a more rudimentary fashion to organize 
and obtain many images and to utilize the averaging features. It was not 
intended to be used as a means to generate 3D reconstructions, as it is more 
frequently used in cryogenic electron microscopy. TEM images were imported 
with the correct accelerating voltage of 100 kV, molecular weight of 440 kDa, 
Å/pixel, and microscope Cs values. Single particles were selected using the 
“interactive boxing” function. The appropriate box size was determined based 
on the number of pixels that made up the diameter of the particles. An 
appropriate size was chosen to allow significant background to be included to 
accommodate the processing functions. Box sizes were based on the list of 
appropriate sizes on the EMAN2 wiki. These stacks of images were saved as 
bdb files for further processing. Stacks were iteratively run through the 
“automated fitting”, “interactive tuning”, and “generate structure factor” 
functions until the defocus and B-factor matched well. Typically this took two 
or three iterations due to the lower resolution of the negatively stained images. 
These stacks were opened in the “Build particle set” function as wiener filtered 
images. “Bad particles” were manually removed before the reconstruction. “Bad 
particles” were arbitrarily defined as obscure, incomplete, or off center images 
that would likely be detrimental to the final reconstruction. Finally, the 
“generate classes function” was executed to generate a reference free class 
average. Here the phase flipped-hp data was chosen for the reconstruction, the 
class number was set to 10, and 8-15 refinement iterations were performed. 
Again, more information is available on the EMAN2 wiki.169  
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2.3. Results and Discussion   
2.3.1. WT Purification  
All of the Bfr proteins were expressed and purified in the Honek 
laboratory. The genes for WT and His6-tag Bfr were previously generated by 
Dr. Uthaiwan Suttisansanee in the Honek laboratory.141 In brief, the WT Bfr 
gene was inserted into a pET 22b vector using NdeI and BamHI cut sites, and 
was transformed into an E. coli BL21 cell line for over expression. The pET 22b 
vector contained the Lac operon, which allowed for the use of IPTG to induce 
overexpression of desired proteins. Before expression, WT Bfr was sent for 
sequencing to confirm the sequence (Table 2). After cell lysis steps the protein 
was purified using two or three column types.   
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Table 2: Sequencing results for the WT Bfr, His6-tag Bfr, BfrM, and S-Bfr. The gene is highlighted 
in bolded, and the associated protein translations are shown below in italics with the methionine 
residues highlighted in bold. 
WT Bfr NNNNNgNNcgtaNcaTTcCnCTCTaganaTAATTTTGTTtaACTTTAAGAAGGAGATATACATATGAAAGGTGAT
ACTAAAGTTATAAATTATCTCAACAAACTGTTGGGAAATGAGCTTGTCGCAATCAATCAGTACTTTCTCCAT
GCCCGAATGTTTAAAAACTGGGGTCTCAAACGTCTCAATGATGTGGAGTATCATGAATCCATTGATGAGAT
GAAACACGCCGATCGTTATATTGAGCGCATTCTTTTTCTGGAAGGTCTTCCAAACTTACAGGACCTGGGCAA
ACTGAACATTGGTGAAGATGTTGAGGAAATGCTGCGTTCTGATCTGGCACTTGAGCTGGATGGCGCGAAG
AATTTGCGTGAGGCAATTGGTTATGCCGATAGCGTTCATGATTACGTCAGCCGCGATATGATGATAGAAAT
TTTGCGTGATGAAGAAGGCCATATCGACTGGCTGGAAACGGAACTTGATCTGATTCAGAAGATGGGCCTG
CAAAATTATCTGCAAGCACAGATCCGCGAAGAAGGTTGAGGATCCGAATTCGAGCTCCGTCGACAAGCTTG
CGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGT
TGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTT
GCT 
MKGDTKVINYLNKLLGNELVAINQYFLHARMFKNWGLKRLNDVEYHESIDEMKHADRYIERILFLEGLPNLQDLGK
LNIGEDVEEMLRSDLALELDGAKNLREAIGYADSVHDYVSRDMMIEILRDEEGHIDWLETELDLIQKMGLQNYLQ
AQIREEG  
His6-tag 
Bfr 
NNNatgNGNcGtaNcNATTCCCCTCTAgAnaTAATTTTGTTtaACTTTAAGAAGGAGATATACATATGAAAGGT
GATACTAAAGTTATAAATTATCTCAACAAACTGTTGGGAAATGAGCTTGTCGCAATCAATCAGTACTTTCTC
CATGCCCGAATGTTTAAAAACTGGGGTCTCAAACGTCTCAATGATGTGGAGTATCATGAATCCATTGATGA
GATGAAACACGCCGATCGTTATATTGAGCGCATTCTTTTTCTGGAAGGTCTTCCAAACTTACAGGACCTGGG
CAAACTGAACATTGGTGAAGATGTTGAGGAAATGCTGCGTTCTGATCTGGCACTTGAGCTGGATGGCGCG
AAGAATTTGCGTGAGGCAATTGGTTATGCCGATAGCGTTCATGATTACGTCAGCCGCGATATGATGATAGA
AATTTTGCGTGATGAAGAAGGCCATATCGACTGGCTGGAAACGGAACTTGATCTGATTCAGAAGATGGGC
CTGCAAAATTATCTGCAAGCACAGATCCGCGAAGAAGGTCTCGAGCACCACCACCACCACCACTGAGATCC
GGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCT
TGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGAATGGGAC
GCGCC 
MKGDTKVINYLNKLLGNELVAINQYFLHARMFKNWGLKRLNDVEYHESIDEMKHADRYIERILFLEGLPNLQDLGK
LNIGEDVEEMLRSDLALELDGAKNLREAIGYADSVHDYVSRDMMIEILRDEEGHIDWLETELDLIQKMGLQNYLQ
AQIREEGLEHHHHHH  
BfrM NNNNNNNNNNNNNNatTCCCCTCTAgaataATTTTGTTTAACTTTAAgaAGGAGATataCATATGAAAGGTGAC
ACGAAAGTCATTAACTATCTGAACAAACTGCTGGGCAACGAACTGGTCGCCATCAATCAATACTTCCTGCAC
GCACGCCTGTTTAAAAACTGGGGCCTGAAACGTCTGAATGATGTCGAATACCATGAAAGTATCGATGAAAT
GAAACACGCCGACCGTTACATTGAACGCATCCTGTTCCTGGAAGGTCTGCCGAACCTGCAGGATCTGGGCA
AACTGAATATTGGTGAAGACGTTGAAGAACTGCTGCGTAGCGATCTGGCACTGGAACTGGACGGCGCTAA
AAACCTGCGCGAAGCGATCGGTTATGCCGATAGCGTGCATGACTACGTTTCTCGTGATCTGCTGATTGAAAT
CCTGCGCGATGAAGAAGGCCACATTGACTGGCTGGAAACCGAACTGGACCTGATCCAAAAACTGGGTCTG
CAAAACTACCTGCAAGCACAAATCCGTGAAGAAGGCCTCGAGCACCACCACCACCACCACTGAGATCCGGC
TGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGG
GGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGANGAACTATATCCGGATTGGCGnAATGGGACGC
GCCCTGTAGCGGCNCATTAAGCGCGGCGGGTGTGGTGGTNACNCGCAGCGTGACNGCTACACTTGNNANC
GCCNTANCGNNNGCN 
MKGDTKVINYLNKLLGNELVAINQYFLHARLFKNWGLKRLNDVEYHESIDEMKHADRYIERILFLEGLPNLQDLGKL
NIGEDVEELLRSDLALELDGAKNLREAIGYADSVHDYVSRDLLIEILRDEEGHIDWLETELDLIQKLGLQNYLQAQIRE
EGLEHHHHHH 
S-Bfr ATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGC
ACATGGACAGCCCAGATCTACATATGAAAGGTGATACTAAAGTTATAAATTATCTCAACAAACTGTTGGGA
AATGAGCTTGTCGCAATCAATCAGTACTTTCTCCATGCCCGAATGTTTAAAAACTGGGGTCTCAAACGTCTC
AATGATGTGGAGTATCATGAATCCATTGATGAGATGAAACACGCCGATCGTTATATTGAGCGCATTCTTTTT
CTGGAAGGTCTTCCAAACTTACAGGACCTGGGCAAACTGAACATTGGTGAAGATGTTGAGGAAATGCTGC
GTTCTGATCTGGCACTTGAGCTGGATGGCGCGAAGAATTTGCGTGAGGCAATTGGTTATGCCGATAGCGTT
CATGATTACGTCAGCCGCGATATGATGATAGAAATTTTGCGTGATGAAGAAGGCCATATCGACTGGCTGGA
AACGGAACTTGATCTGATTCAGAAGATGGGCCTGCAAAATTATCTGCAAGCACAGATCCGCGAAGAAGGT
CTCGAGCACCACCACCACCACCACTGAGATCCGGCTG 
MKETAAAKFERQHMDSPDLHMKGDTKVINYLNKLLGNELVAINQYFLHARMFKNWGLKRLNDVEYHESIDEMK
HADRYIERILFLEGLPNLQDLGKLNIGEDVEEMLRSDLALELDGAKNLREAIGYADSVHDYVSRDMMIEILRDEEGHI
DWLETELDLIQKMGLQNYLQAQIREEGLEHHHHHH  
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Originally, WT Bfr was purified using an anion exchange column and a 
size exclusion column, but this was later adapted to an anion exchange column 
and a hydroxyapatite column. The anion exchange column used was a Bio Rad 
UnoTM-Q1 column. To this column, volumes of supernatant from the 
homogenized cells were injected at 1 ml increments. Fractions were then 
examined on an SDS-PAGE gel to determine the purity of the protein (Figure 
2.2). Bfr protein was observed in both the flow through and the eluted fractions. 
Only the eluted fractions were collected since there was less contamination. 
These fractions were collected and concentrated using an Amicon stirred cell 
pressure concentrator with a Millipore Ultrafiltration membrane with a 10 kDa 
cut off. This collected protein was loaded onto a GE SephacrylTM S-400 HR 
column. These fractions were analyzed with SDS-PAGE to examine the purity 
of the WT Bfr (Figure 2.3). The Rf for the 24mer and dimer peaks on this 
column were 0.88 and 0.73, respectively, with a void volume of 253.68 ml. 
There appeared to be fractions that contained pure WT Bfr protein. These 
fractions were concentrated as before, and then the correct molecular weight of 
18495 Da was determined with the use of an ESI-QTOF mass spectrometer 
(Figure 2.4). The deconvoluted spectrum revealed a peak with a molecular 
weight of 18494 Da, whereas the calculated weight was 18495 Da. Deviation of 
a single mass unit can be expected in lower resolution mass spectrometry. In 
addition to purifying WT Bfr, re-incorporation of heme into Bfr was performed. 
As is discussed below, heme was expected to be favourable in promoting the 
formation of the 24mer. The heme was reconstituted back into Bfr using a 
previously derived method, and subsequently used for encapsulation studies.163  
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Figure 2.2: SDS-PAGE of WT Bfr fractions (A) from a Bio-Rad UnoTM-Q anion exchange resin (B). 
The lanes listed from left to right were fractions 6B, 8B, 25B, 26B, 33B, and the Precision Plus 
ProteinTM ladder from Bio-Rad. The largest bands above the 15 kDa marker were WT Bfr. 
Fractions from and between lanes 3, 4, and 5 were pooled and concentrated for the next step  
 
Figure 2.3: SDS-PAGE of WT Bfr (A) fractions from a GE SephacrylTM S-300 HR size exclusion 
chromatography, which had three samples injected sequentially (B). Lanes from left to right were 
Bio-Rad Procession Plus ProteinTM ladder, fractions 63A, 70A, 77A, 85A, 89A, 2B, 7B, 16B, 20B, and 
27B. Fractions from 77A to 85A (volumes 150-210 ml, 330-370 ml, and 480-530 ml) were collected 
and analysed with MS.     
 
Figure 2.4: Mass spectrum of WT Bfr obtained from a Waters Micromass nanospray ESI-QTOF. 
The raw spectrum (A) showed a Gaussian distribution of multiply charged WT Bfr. The processed 
spectrum (B) was deconvoluted using the MaxEnt 1 tool supplied with the MassLynx software. The 
deconvoluted mass was measured as 18494 Da, one mass unit off of the correct mass of 18495 Da.   
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 After a series of WT Bfr purifications, an increasing nucleotide 
contaminant was observed. The nucleotide contaminant was identified by a high 
260/280 ratio of 1.60, and a fluorescent band was visible when running an 
agarose gel (Figure 2.5).To remedy this issue, several attempts were made to 
remove this contaminant by filtration. After dialysis for over 24 hours, and 
buffer exchanging with an Amicon concentrator with 500 ml of fresh buffer the 
260/280 ratio remained the same. Use of a third column was entertained to try 
and selectively bind either the nucleotide or the protein. A Bio-Rad CHTTM 
ceramic hydroxyapatite type II resin was used, which was reported to bind 
DNA. The nucleotide contaminated WT Bfr from the size exclusion 
SephacrylTM S-300 HR column was used to test the hydroxyapatite column. 
Fractions were examined on SDS-PAGE, and then on ESI-QTOF MS to 
determine the mass of WT Bfr (Figure 2.6). It was determined that the protein 
was pure and absent of nucleotide contamination by the low 260/280 ratio of 
1.03. In subsequent purifications of WT Bfr the size exclusion step was 
removed entirely, and only the anion exchange column and hydroxyapatite 
columns were used. This greatly reduced the preparation and run time for 
purification. The origin of the nucleotide contaminant was not investigated.   
      
Figure 2.5: Agarose gel of a purified WT Bfr protein prep showing nucleotide contamination. Lanes 
from left to right were the contaminated WT Bfr sample, 1kbp Fermentas GeneRulerTM, and 100 Bp 
Fermentas GeneRulerTM.   
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Figure 2.6: SDS-PAGE of WT Bfr (A) fractions from a Bio-Rad CHTTM ceramic hydroxyapatite 
type II resin (B). Lanes, from left to right, were pure His6-tag Bfr, fractions 54A, 68A, 73A, 74A, 
pure His6-tag Bfr, and Bio-Rad Procession Plus ProteinTM ladder. Fractions from lanes 4 and 5 were 
collected and analyzed with MS. 
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3.3.2. S-Bfr Purification  
The S-Bfr construct was designed for the purposes of labelling the 
exterior of Bfr. S-Bfr was designed with an S-tag on the N-terminus, which 
faces the exterior surface. By making this N-terminal extension, a Gln residue 
on the tag would become externally exposed. It was hypothesized that this Gln 
would be available for enzymatic labelling with a transglutaminase (TGase). In 
order to generate an S-tag onto His6-tag Bfr Anthony Petrie, of the Honek 
laboratory, designed primers to add a BglII cut site at the N-terminus of Bfr. A 
BglII cut site would enable the correct, in-frame, placement of the His6-tag Bfr 
gene into a pET29b vector containing an N-terminal S-tag. In addition to the S-
tag, a His6-tag was kept on the C-terminus to simplify downstream purification 
procedures. In order to generate this cut site a point mutation was made 
upstream of the original initiator codon, and in consequence four additional 
residues, PDLH, were added after the S-tag. In total, there were 20 amino acids 
added, which increased the molecular weight to 21884 Da. Anthony Petrie made 
this mutation and prepared the gene in a pET29b vector. The correct gene was 
confirmed by Anthony Petrie through sequencing of the plasmid. This was 
transformed into E. coli BL21 cells and expressed, as before, using IPTG. Cells 
were lysed and the supernatant treated with a 70 °C heat shock step, which S-
Bfr stable to. S-Bfr was purified using a GE HisTrapTM column, using the same 
method as the His6-tag Bfr purification procedure. This resulted in pure S-Bfr 
protein, which was concentrated and analyzed on ESI-Orbitrap MS to confirm 
the correct mass. A single mass of 21883.6 kDa was observed, signifying the 
expression and purification of the correct protein (Figure 2.7). Fragmentation of 
S-Bfr was observed after leaving a solution of S-Bfr at 4 °C for a week. It was 
suspected that the fragmentation was a result of a trace amount of contaminant 
protease. Two protease inhibitors were examined by a student under my 
supervision, Hawa Gyamfi of the Honek laboratory. The inhibitors were 
ethylenediaminetetraacetic acid (EDTA), and phenylmethanesulfonyl fluoride 
(PMSF), tp determin if there was either a metalloprotease, or serine protease, 
respectively. The concentrations used were 1 mM and 5 mM for EDTA and 
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PMSF, respectively. After incubating at room temperature, 23 °C, for five days 
the inhibitor-less control showed fragmentation, similar to S-Bfr with PMSF 
inhibitor. BfrM with EDTA lacked fragmentation, which indicated that it was 
likely a metalloprotease (Figure 2.8).     
 
Figure 2.7: MS of purified S-Bfr from a GE HisTrapTM column using a Thermo Scientific Q 
ExactiveTM. The raw spectrum (A) was deconvoluted (B) and revealed a mass of 21883.7 Da, which 
was close to the calculated mass of 21884.7 Da. The elution profile from a GE HisTrapTM column 
was similar to that seen with His6-tag Bfr elution (C).   
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Figure 2.8: MS of S-Bfr with PMSF and EDTA protease inhibitors. An inhibitor-less control (A), 
along with two inhibitors: PMSF (B), and EDTA (C) were used. It was observed after a week of 
incubation at 23 °C that the control and PMSF trial showed a high level of fragmentation, whereas 
the EDTA trial showed no fragmentation, as can be observed by analysis of the deconvoluted 
spectrums. 
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3.3.3. Streptavidin Encapsulation within Bfr 
Initial conditions for encapsulation of SF were explored by monitoring 
the ratio of peaks on size exclusion chromatography. The peak ratio was based 
on the measured absorbance value at 495 nm, which was the absorption maxima 
for SF, of the eluted peaks on a GE SephacrylTM S-300 HR size exclusion 
column. Free SF would elute where the observed “second peak” would elute 
after an encapsulation trial, which corresponded to unsuccessfully encapsulated 
SF. The first peak, therefore, should have corresponded to the encapsulated SF, 
which eluted at the same time point as 24mer Bfr. By dividing the first peak by 
the second the peak ratio was obtained, which was used as an indicator for the 
amount of SF that was encapsulated within Bfr. Two conditions were explored 
when encapsulating SF: the effect of the ratio of His6-tag to WT Bfr, and the 
concentration of guanidine hydrochloride (GndHCl). Since the tag on His6-tag 
Bfr was facing the interior it was likely that this would decrease the inner 
diameter, as shown previously in computer simulations.141 By modulating the 
ratio between WT and His6-tag, it was possible to optimize encapsulation 
conditions, trading off between crowding and the number of affinity 
interactions. Upon declustering of the self-assembled units, it would be possible 
to generate a hybrid of WT and His6-tag Bfr upon reformation of the cage 
structure.  
SF encapsulation was analyzed with varying ratios of His6-tag to WT 
Bfr, which were separated on a GE SephacrylTM S-300 HR column (Figure 2.9). 
The Rf of the first and second peak were 0.47 and 0.70, respectively, with a void 
volume of 99.05 ml.  There was a subtle difference between the 80/20, 60/40, 
and 50/50 mixtures of His6-tag/WT, with peak ratios of 0.76, 0.80, and 0.81, 
respectively. Although the 80/20 and 50/50 were very similar in the ratio of the 
eluted peaks, 60/40 was chosen as the ideal ratio. The encapsulated SF peak 
ratios for 40/60 and 20/80 His6-tag/WT were 0.63 and 0.54, respectively. A 
control was also run with SF and His6-tag Bfr, which did not contain any 
biotin-XNTA. It was observed in this control that only a single peak eluted from 
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the GE SephacrylTM S-300 HR column at the same time as free SF and the 
observed second peak in the encapsulation trials.  
 
Figure 2.9: Varying ratios of His6-tag/WT Bfr with encapsulated SF run on a GE SephacrylTM S-300 
HR resin. The elution was monitored with four wavelengths, 280 nm, 260 nm, 418 nm, and 495 nm. 
Displayed here is the 495 nm monitored wavelength, which corresponded to the fluorescein on SF.  
 Concentrations of GndHCl to decluster 24mer His6-tag/WT Bfr were 
varied in order to examine the amount that was necessary for proper 
encapsulation of SF. If less GndHCl was required for encapsulation, then it 
might be more advantageous to perform encapsulation experiments in less harsh 
conditions. Several concentrations of GndHCl were used to evaluate the 
importance of using this chemical disruptant for exposure of the inner surface of 
Bfr by declustering. All of these trials were performed using a 60/40 ratio of 
His6-tag to WT, with SF, Biotin-XNTA, and nickel sulfate. Five concentrations 
were explored, 8 M, 4 M, 2 M, 1 M, and 0 M, keeping the conditions otherwise 
identical between these trials (Figure 2.10). The no biotin-XNTA control was 
also included in this graph as a point of comparison to the rest of the data. As 
was observed with the elution pattern, even total absence of GndHCl seemed to 
yield some amount of encapsulated SF. This was interesting because it was 
thought that the His6-tag would largely be unexposed in buffered aqueous 
solution. This was likely due to some of the inherent equilibrium between the 
24mer and the dimer state of Bfr. Dimer Bfr would have had an exposed His6-
tag, and would have been able to interact with the Biotin-XNTA. This process 
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was, however, not as efficient at encapsulation as the in the presence of 
GndHCl. Peak ratios were 0.70, 0.64, 0.60, 0.60, and 0.49 for 8 M, 4 M, 2 M, 1 
M, and 0 M GndHCl, respectively. It was possible to encapsulate in all of these 
conditions, but it seemed to be more favourable to do so in higher amounts of 
GndHCl. This seemed to indicate that the interaction between His6-tag Bfr and 
SF was favourable enough that even under non-declustering conditions some SF 
would become encapsulated. The use of 60/40 His6-tag/WT conditions with 8 
M GndHCl were scaled up by five times, and it was observed in some cases to 
encapsulate quantities of SF that had peak ratios as high as 1.20 (Figure 2.11). 
 
Figure 2.10: Varying concentrations of GndHCl during encapsulation of SF within His6-tag/WT Bfr. 
The samples were run on a GE SephacrylTM S-300 HR resin while monitoring the 495 nm 
wavelength, specific for the SF marker.  
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Figure 2.11: Encapsulation of SF within 60/40 His6-tag/WT Bfr using two declustering agents:  
GndHCl and a 40 °C temperature change. These samples of encapsulated SF used 60/40 His6-
tag/WT Bfr and were run on GE SephacrylTM S-300 HR resin. The wavelength monitored, 495 nm, 
was specific for the fluorescein label found on SF. 
 
An absence of GndHCl during the encapsulation procedure resulted in 
some small levels of SF being encapsulated. It was suspected that an alternative, 
possibly less severe, conditions could be utilized for encapsulation. Since both 
Bfr and SF are known to be heat stable, a temperature based method to decluster 
Bfr was attempted. Using a hot water bath at 40 °C the mixture of host, guest, 
and linker was left for 90 minutes. Instead of needing to dialyze excess GndHCl 
out, it was left at room temperature to cool and was then run on size exclusion 
(Figure 2.11). The peak ratio for the 40 °C temperature based encapsulation trial 
was 0.96, which was very comparable to some of the other 8 M GndHCl trials. 
This demonstrated that it was possible to use another method to encapsulate the 
SF guest molecule, which may prove to simplify preparation time. The 
encapsulated samples prepared here were used for future experiments with TEM 
and fluorescence quenching. 
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2.3.2. GNP Encapsulation within Bfr  
 Two commercial gold nanoparticles (GNP) were investigated as 
inorganic guest particles to encapsulate in Bfr. The sizes of these nanoparticles 
were 1.8 and 5 nm, each of which had NTA ligands attached to the surface 
through a proprietary polymer linker. The 1.8 and 5 nm linker distances were 
0.7-1 nm and 1.5 nm, respectively. This made the final diameter of the 1.8 and 5 
nm nanoparticles 2.8 and 8 nm, respectively. For these nanoparticles, 2.8 nm 
was well within the size limitations of the interior 8 nm core of Bfr, whereas 8 
nm was at the very extreme of allowable sizes. The 1.8 nm GNP was explored 
first by a student under my supervision, Robert Taylor, as it was suspected to be 
a better candidate for encapsulation within Bfr. This GNP appeared brown-red 
in colour and had a reported absorption maxima at 420 nm. This maxima, 
unfortunately, overlapped with the heme present in Bfr reconstituted with heme. 
Thus, for these experiments His6-tag and WT bfr were utilized in the absence of 
heme in their structure. Therefore any signal at 420 nm on chromatograms 
should have been a result of the presence of the 1.8 nm GNP. The first step was 
to determine the optimal ratio of His6-tag to WT for encapsulating 1.8 nm GNP.    
 Robert Taylor explored the ratios of His6-tag and WT to optimize the 
conditions for 1.8 nm GNP encapsulation. The method for encapsulation used 8 
M GndHCl to decluster the 24mer Bfr to expose the interior His6-tag. This was 
then incubated in the presence of the 1.8 nm GNP and nickel sulfate and then 
dialyzed into 50 mM Tris, 100 mM NaCl buffer at pH 8.0. This procedure 
mirrored that which was used for the encapsulation of SF in the previous 
experiment. Before the encapsulation trial was performed, absorption spectra for 
both 1.8 and 5 nm GNP were taken (Figure 2.12). Curiously, the absorption 
spectra for the 1.8 nm GNP did not contain a distinctive peak at 420 nm, as was 
stated in the specifications for the product. Whereas, the 5 nm GNP clearly 
contained a 518 nm absorption peak. Both GNPs, however, exhibited high 
absorption in the UV range. For future experimental identification, 518 nm 
wavelength was used to specifically identify the 5 nm GNP, but 420 nm could 
not be used for the 1.8 nm GNP. The 1.8 nm GNP encapsulation was examined 
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with several ratios of His6-tag and WT Bfr to optimize conditions. Ratios of 
His6-tag/WT Bfr explored were 0/100, 10/90, 50/50, 70/30, and 100/0. Each of 
these trials used GndHCl to decluster as described before, and solutions were 
dialyzed into 50 mM Tris, 100 mM NaCl buffer at pH 8.0 for 24 hours, and then 
eluted through a GE SephadexTM S-300 HR column (Figure 2.13). The first 
peak in this chromatogram was attributed to the 24 mer Bfr, the second to the 
free 1.8 nm GNP, and the third to dimer Bfr. This equilibrium between fully 
formed 24mer and dimer Bfr had been observed previously.159,170 Examining 
Figure 2.13 seemed to suggest that Bfr was more in the 24mer state when the 
His6-tag/WT ratios were 10/90 and 0/100. As the ratios were shifted to higher 
His6-tag Bfr content the dimer peaks appears to dominate in the 
chromatograms. As a reference, the pure 1.8 nm GNP was run by itself and 
seemed to elute slightly earlier than the dimer peak observed for Bfr. These trial 
runs were also examined with TEM to visualize the presence of encapsulated 
1.8 nm GNP in Bfr.  
 
 
Figure 2.12: UV-Vis absorption spectrum of 1.8 and 5 nm GNP in aqueous buffer. The 5 nm GNP 
showed a clear absorption peak at the manufacturer specified absorption maxima of 518 nm. The 1.8 
nm GNP, however, showed no observable 420 nm absorption peak, contrary to manufacturer 
specification. 
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Figure 2.13: Encapsulation trials of 1.8 nm GNP with varying ratios of His6-tag/WT Bfr. The trials 
were run on a GE SephacrylTM S-300 HR with the monitored wavelength of 280 nm.  
In addition to these initial trials, further experiments were conducted 
altering the conditions for encapsulation. Encapsulation in the absence of 
GndHCl at varied temperatures were examined to rule out the possibility that 
GndHCl was negatively affecting association between 1.8 nm GNP and Bfr, and 
to explore alternative means of encapsulation. Three temperatures, 4, 25, and 50 
°C were used to encapsulate 1.8 nm GNP in the absence of GndHCl using a 
ratio of His6-tag/WT Bfr of 50/50 (Figure 2.14). In these trials the previously 
observed dimer peak appeared to virtually disappear. This very dramatic change 
in elution profile may have resulted because the conditions were less disruptive. 
Using temperature as a strategy for encapsulation could potentially be 
advantageous as a future encapsulation methodology since it was very easy to 
regulate, and may be less disruptive.   
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Figure 2.14: Encapsulation of 1.8 nm GNP under varying temperatures. The encapsulated 1.8 nm 
GNP was run on a GE SephacrylTM S-300 HR resin, with a monitored wavelength of 280 nm. The 
three temperatures used were 4, 25, and 50 °C, each using a 50/50 His6-tag/WT ratio.      
 A control trial for 1.8 nm encapsulation was performed without any 
nickel sulphate present. In the absence of Ni2+ no coordination site on the 
surface of the 1.8 nm GNP would be available for the histidine groups on the 
inner surface of Bfr. (Figure 2.15). It was quite clear that there was a shoulder 
within the dimer peak of the control run. This shoulder was attributed to the free 
1.8 nm GNP, which was not coordinated by any Bfr. The pure 1.8 nm GNP had 
an elution time identical to this shoulder on the dimer peak of the control.  
 
 
Figure 2.15: Negative control of encapsulated 1.8 nm GNP in Bfr. The samples were run on GE 
SephacrylTM S-300 HR column, and the monitored wavelength was 280 nm. The control underwent 
the same encapsulation conditions as previously, but without the presence of nickel sulfate.  
After much trial and analysis with attempts to encapsulate 1.8 nm GNP there 
was no clear evidence of successful, or proficient encapsulation within Bfr. 
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Subsequently, the 5 nm GNP candidate was explored briefly to attempt 
encapsulation of a GNP. The approach taken was meant to quickly assess 
whether it was possible or not to encapsulate this extremely large guest particle. 
The first attempt was with GndHCl as the declustering agent, and with a 60/40 
ratio of His6-tag/WT Bfr, as has been shown previously to be optimal for both 
SF and ProQ® Sapphire 365 oligohistidine gel stain.141 Attempts were also 
made to encapsulate without GndHCl, but with temperature increase, as with the 
1.8 nm GNP. After encapsulation trials using GndHCl and temperature change 
the resulting solutions were separated on a GE SephadexTM S-300 HR column 
(Figure 2.16). It was observed that the elution of the 5nm GNP was slightly 
earlier when using temperatures changes, which suggested that the GNP was 
associating with Bfr. Although it was thought that encapsulation of the larger 5 
nm GNP would be less likely, it appeared to interact favourably with Bfr. TEM 
experiments would later confirm that there was indeed proper encapsulation, an 
interesting difference since the smaller 1.8 nm GNP did not appear to 
encapsulate.   
 
Figure 2.16 Encapsulation of 5 nm GNPs in Bfr separated on a GE SephacrylTM S-300 HR resin. 
Two conditions were used, one with GndHCl as the declustering agent, one without. Each trial was 
monitored at the wavelengths of 418 nm and 518 nm, which corresponded to the heme in Bfr 
absorption maxima, and the 5 nm GNP absorption maxima, respectively. There was a slight shift in 
the elution time of 5 nm GNP to an earlier time point when no GndHCl was used.   
 In addition to the encapsulation conditions explored above, two control 
experiments were also conducted. One control was performed with 100% His6-
tag Bfr, and another with 100% WT Bfr (Figure 2.17). Here a subtle, but 
observable shift in the elution times between the 100% His6-tag and the 100% 
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WT was observed. There was a clear shift in the 5 nm GNP elution between the 
two. The WT control had a 5 nm GNP elution time that was very similar to the 
elution time of the pure 5 nm GNP. The elution of the 100% His6-tag Bfr, as 
indicated by the 420 nm monitored wavelength, mirrored that of the 
encapsulated 5 nm GNP. TEM experiments would confirm encapsulation of 
GNP with the His6-tag Bfr control, but not with the WT control, which is 
elaborated on below. The efficiency of encapsulation of the 5 nm GNP was 
calculated using the extinction coefficient at 518 nm of 1.0x107 M-1cm-1, and 
the concentration of Bfr using the heme extinction coefficient of 1.09x105 (M-
1cm-1) and extrapolating the Bfr concentration from this.134 The yield was 
calculated to be approximately 13%, or one GNP encapsulated in every seven-
eight Bfr cages. Use of 100% His6-tag Bfr appeared to be the optimal ratio for 5 
nm GNP encapsulation.      
  
Figure 2.17: Encapsulated 5 nm GNP with a negative control separated on a GE SephacrylTM S-300 
HR resin. The elution was monitored with wavelengths 418 nm and 518 nm, corresponding to heme 
in Bfr, and 5 nm GNP, respectively. Two controls were run, one with 100% His6-tag Bfr, and one 
with 100% WT Bfr. The 100% His6-tag Bfr trial showed a clear shift in the elution time of the 5 nm 
GNP. 
63 
 
2.3.3. Fluorescence Measurements of Encapsulated SF 
Streptavidin, a large tetrameric protein, was chosen as a guest 
protein to probe the capabilities of Bfr to accommodate entire proteins. By 
encapsulating SF it would aid develop of methodologies to encapsulate 
other complex and large guest molecules. Streptavidin has an approximate 
size of 5-6 nm 152, which was thought to be within the capabilities of the 8 
nm interior diameter of Bfr to contain. A fluorescent label on streptavidin 
was used to permit fluorescence quenching measurements to determine the 
degree of protection of streptavidin from the external environment. 
A commercially available fluorescein-labelled streptavidin, SF, was 
utilized to track and analyze encapsulation within Bfr (Figure 2.18). The 
first eluted peak from size exclusion chromatography exhibited an 
absorbance corresponding to the absorption maxima of both fluorescein 
(495 nm) and Bfr (418 nm) (Figure 2.19). Control experiments without 
Biotin-XNTA did not reveal the same absorption peaks. Analysis of these 
results indicated that SF was indeed associating with Bfr, and that both the 
His6-tag and Biotin-XNTA were essential for this association.  
 
 
Figure 2.18: Streptavidin, a tetrameric beta barrel protein, has four biotin binding sites, which 
were utilized for the affinity mediator biotin-XNTA to encapsulate SF. Each beta-barrel is 
presented in a different colour, and the biotin molecules are displayed as red spheres. Image 
generated using PDB ID 3RY1 in pymol.   
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Figure 2.19: Absorption spectrum of encapsulated SF and free SF. There was an absorption 
peak at 495 nm in the encapsulated spectra, which corresponded to the absorption maxima of 
the fluorescent label of SF. This suggested that SF had been encapsualted within Bfr.   
 Each SF encapsulated sample was evaluated using fluorescence 
quenching studies. A lack of quenching would provide evidence that SF was 
protected by a protein-cage barrier, i.e. Bfr. Three quenching agents were 
used to evaluate encapsulation: iodide, dabsyl-glutamate, and black hole 
quencher® 10 (BHQ®10). Iodide is a static quencher171, while dabsyl-
glutamate and BHQ®10 both quenched based on Förster resonance energy 
transfer.172,173 Dabsyl chloride was labelled with glutamate to ensure that it 
would not react with free amines on either of the proteins in solution. 
Experimental and theoretical data were used to calculate a theoretical FRET 
distance for both dabsyl-glutamate and BHQ®10 with SF. Using a model 
derived in the Visser lab, a theoretical FRET distance was calculated for 
both dabsyl-glutamate and BHQ®10.174 FRET distances were 
approximately 4 and 5 nm for dabsyl-glutamate, and BHQ®10, respectively. 
The dipole orientation factor, refractive index of the medium, and the 
quantum yield were all approximated to 0.667, 1.4, and 0.5, respectively. 
Analysis of the x-ray structure of Bfr135 provided an estimation of the 
protein shell width to be between 2.5 and 3 nm without solvation radius, 
electrostatics, or other factors considered. Both quenchers showed potential 
to quench fluorescence at this distance, though not all parameters were 
considered in this theoretical evaluation.  
 Both encapsulated and non-encapsulated SF were titrated with 
quencher and again separately with buffer to control for dilution effects. 
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Iodide, dabsyl-glutamate, and BHQ®10 were plotted with both the 
encapsulated and exposed SF (Figure 2.20). Encapsulated SF exhibited 
almost total absence of quenching over the course of titration of iodide, 
whereas Dabsyl-glutamate showed some quenching over titration, and 
BHQ®10 showed essentially complete quenching. When compared to the 
theoretical FRET distances and the quenching trend observed for Dabsyl-
glutamate and BHQ®10 it is reasonable to expect that more quenching 
should be observed for BHQ®10 due to its predicted larger FRET distance. 
Therefore the quenching affect with BHQ®10 should not necessarily 
indicate exposure of SF. 
 
 
Figure 2.20: Titrations of quencher into solutions of free SF and encapsulated SF were 
transformed into Stern-Volmer plots. Titration of three different quenchers were used to 
validate encapsulation of SF in Bfr. Iodide (A) showed an apparent total absence of quenching, 
whereas dabsyl-glutamate (B) and BHQ10 (C) showed some level of quenching. The expected 
reason for increased quenching between dabsyl-glutamate and BHQ10 was that the two FRET 
based quenchers had FRET distances larger than the protein shell (D). 
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2.3.4. TEM Conditions and Trials 
Confirmation of SF encapsulation was made by employing transmission 
electron microscopy (TEM). This technique had been successfully utilized to 
visualize encapsulated guest molecules within virus-like particles, but had not 
previously been employed for Bfr.175,176 Three TEM stains were used: uranyl 
acetate, molybdic acid, and phosphotungstic acid to highlight Bfr and determine 
the presence of internalized guest molecules within.177 Due to the intrinsic pores 
found in the structure of Bfr, it was hypothesized that atom sized stains would 
be able to penetrate the core, as evidenced with pores on viruses.13,15,124 SF was 
large enough to consume most of the interior space in Bfr and thus any stain 
would be largely excluded from the interior. A lack of stain in the interior would 
indicate the encapsulation of SF, as monitored by TEM. 
Analysis of commercial apo-ferritin and apo-Bfr by TEM showed 
obvious stain penetration with both uranyl acetate and molybdic acid into the 
interiors of these multisubunit proteins (Figure 2.21). The penetration of stain 
confirmed that single atom stains were small enough to transit across the native 
pores found in intact Bfr. In addition to these preliminary trials a new image 
processing technique was explored. This processing technique is called single 
particle analysis, and the software used to explore this technique was called 
EMAN2.178 This technique was first evaluated with apo-Bfr without 
encapsulated materials, and improved TEM-obtained image quality (Figure 
2.22). The measured size of apo-Bfr matched well with crystal data, giving an 
outer diameter of 11.7 nm and inner diameter of 4.8 nm. 
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Figure 2.21: Negatively stained TEM images of horse apo-ferritin and apo-Bfr. The stain used with 
apo-ferritin (A) was uranyl acetate, and molybdic acid was used with apo-Bfr (B). The stain clearly 
penetrated the interior of apo-Bfr, which made Bfr appear as a donut shaped 2-D object.   
 
Figure 2.22: A negatively stained image of apo-Bfr using 0.5 % molybdic acid (A). Multiple images 
were used, and hundreds of single particles gathered (B) were used to generate a reference free class 
in EMAN2 (C). Measurement of this final image matched the expected size of apo-Bfr based on 
crystallographic data179.
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This staining technique was used further to probe the presence of 
encapsulated SF within Bfr. After many staining trials, single particle analysis 
was utilized to help clarify images.168 Multiple single images of encapsulated 
SF in Bfr were averaged to try and obtain a clarified picture. A total of 479 
particles from multiple images were analyzed to generate a conserved average 
image of encapsulated SF in Bfr (Figure 2.23). In this case the outer diameter 
remained similar to the native Bfr with a diameter of 11.6 nm, while the inner 
cavity contained a particle of approximately 3 nm in diameter. The expected 
size of SF was larger than this, but image processing may have resulted in some 
reduction of the diameter. Some unprocessed images (Figure 2.23B) showed an 
explusion zone on the interior of Bfr that measured around 4.5 nm, much closer 
to the SF diameter. The unprocessed images for encapsulated SF showed largely 
covered surfaces (Figure 2.23) with potentially exposed regions. These exposed 
regions could also be a result of the non-native conditions of the TEM imaging 
grids. Despite possible incomplete coverage, there was clear evidence of the 
interaction between host and guest molecules. Protection of the guest molecule 
from the external environment as shown by TEM is consistent with conclusions 
drawn from the fluorescence quenching results.  
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Figure 2.23: Single particle analysis of encapsulated SF in Bfr. Over 400 single particles (A) were 
collected and then averaged into three classes. Individual particles selected from the pool of 400 
images that showed to be especially well resolved with a zone of excluded stain in the interior with a 
diameter of approximately 4.5 nm (B). These three classes (C) seem to have an excluded area of stain 
in the interior of approximately 3 nm.    
 One TEM grid condition used in the investigation of encapsulated SF 
resulted in interesting formation of two-dimensional crystals. This may be of 
future importance for study of structural aspects of the Bfr platform. By forming 
two-dimensional crystals one may be able to extract more precise structural data 
by electron beam scattering patterns. A technique of this nature would require 
an equipped electron microscope to collect the diffracted signal. Interestingly, 
crystals were observed using solution conditions with only eight times higher 
concentration of protein than was previously used, and no other additives 
(Figure 2.24). 
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Figure 2.24: Formation of two dimensional crystals of SF encapsulated in 60/40 His6-tag/WT Bfr in 
TEM imaging. Using eight times the concentration of encapsulated SF with 60/40 His6/WT Bfr it 
was possible to generate two dimensional crystals. The image was stained with 0.5 % molybdic acid, 
as before.   
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In addition to a large biological molecule, the encapsultion of inorganic 
1.8 and 5 nm GNP were also investigated.  Commercially available NTA-
surface modified GNPs were studied as paradigms for encapsulation of 
inorganic nanoparticles. TEM was performed on both encapsulated and free 1.8 
and 5 nm GNP. Free GNP was investigated to determine how the polymer 
coating surrounding the GNP would appear in images. Since the polymer 
decorating the GNP with NTA functionalities was organic it would appear as a 
shell surrounding the GNP in a negatively stained image on TEM. This polymer 
coating might have falsely been perceived as Bfr protein coating the GNP. TEM 
analysis of free 5 nm GNP clearly demonstrated that the surrounding polymer 
was not as thick as the protein shell of Bfr (Figure 2.25). When measured, the 
protein layer of Bfr was 3-4 nm in width while the polymer on GNP was only 
detectable on the highest resolved images with a width of approximately 1.5-2 
nm. The 1.8 nm GNP approached the imaging limitations, and seemed to vary 
in diameter (Figure 2.26). It was challenging to acquire images of acceptable 
quality with the 1.8 nm GNP, explainable by a dramatic difference in the 
number of gold atoms found in the 1.8 nm particle.  In addition to the difficulty 
associated with imaging, the 1.8 nm GNPs had high variability in size, with 
particles larger than 1.8 nm by almost two times.  
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Figure 2.25: Comparative TEM images of free 5 nm GNP (A), and empty Bfr (B). There was an 
observable shell around the 5 nm GNP, which was the polymer containing the NTA functionality. 
When measured, this polymer was no larger than 1.8 nm, whereas the thickness of the protein shell 
of Bfr could be as large as 4 nm when measured. 
 
Figure 2.26: TEM images of free 1.8 nm (A) and 5 nm (B) GNP without any negative stain. The 1.8 
nm GNP was measured between 1.8 and 3 nm in diameter, and the 5 nm GNP was measured more 
uniformly around 5 nm in diameter.   
 The 1.8 nm GNP was the first nanoparticle investigated for 
encapsulation within apo-Bfr. The optimal ratio for encapsulation was 
determined previously by Robert Taylor of the Honek laboratory to be 50/50 
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His6-tag/WT Bfr. Trials with 50/50 His6-tag/WT Bfr using 8 M GndHCl as a 
declusterant were imaged after being separated on a GE SephacrylTM S-300 HR 
resin (Figure 2.27). Although there were a select few encapsulated 1.8 nm 
GNPs, the fraction of encapsulation was extremely small. Some particles 
highlighted were as large as 5 nm and ranged within 1.8 to 3 nm. Those 
particles that where 1.8 nm were the most challenging to differentiate in the 
TEM image due to their poor contrast. Thus, further imaging trials were pursued 
to obtain more definitive proof of encapsulation. 
 
Figure 2.27: TEM images of the encapsulated 1.8 nm GNP in apo-Bfr. Highlighted in the boxes are 
the images that have been enlarged in the insert. There were clearly highly electron dense guest 
molecules in the centre of Bfr. This was attributed to GNP because it was more electron dense than 
the background stain.  
  
In order to circumvent the issue of contrast with the small 1.8 nm 
GNP, another staining technique was employed when imaging the 
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encapsulated 1.8 nm GNP. By using the comparatively larger 
phosphotungstic acid (H3PW12O40) negative stain, it was hypothesized that 
the stain would be unable to penetrate the core of Bfr through the native 
pores. To prove this, His6-tag Bfr without any encapsulated guests was 
imaged in the presence of phosphotungstic acid (Figure 2.28). These images 
clearly demonstrated Bfr without the previously observed stain penetration 
of the interior. This was a highly advantageous technique to probe 1.8 nm 
GNP encapsulation because any electron dense spot in the centre of Bfr 
would be the result of encapsulated GNP and not just a stain artifact. In 
addition, stain exclusion would improve the contrast of small GNP within 
Bfr. Attempts were made to image under these conditions using the same 
methodology to prepare encapsulated 1.8 nm GNP as before (Figure 2.29). 
These images, however, revealed no encapsulated GNP. It was decided that 
the declusterant used to disrupt the Bfr shell should be examined for its 
effectiveness. A series of incubation temperatures were used and examined 
on TEM with the phosphotungstic acid negative stain. After analyzing the 
TEM images it was clear that there was not an improvement in the 
efficiency of encapsulation (Figure 2.30). Unfortunately, it was not possible 
to get better encapsulation yields than what was observed here. This was 
especially odd in light of the success of the much larger 5 nm GNP images. 
It seemed to be contrary to logical reasoning that a smaller particle would be 
far less favourable for encapsulation.   
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Figure 2.28: TEM image of apo-Bfr using phosphotungstic acid as a negative stain. Both images 
were generated using 0.5 % phosphotungstic acid. Image B had much more contrast than A, but 
both were generated using the same stain concentration, and importantly both lacked stain 
penetration to the interior. 
 
Figure 2.29: TEM images of 1.8 nm GNP encapsulated in Bfr using phosphotungstic acid. 
Although the encapsulation conditions were similar to previous conditions, the images did not 
reveal any encapsulated 1.8 nm GNP. The insert showed that there was clearly no stain 
penetration. 
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Figure 2.30: TEM images of encapsulated 1.8 nm GNP in Bfr stained with phosphotungstic 
acid. There were scarcely any 1.8 nm GNP encapsulated in Bfr. The insert showed some 
potential evidence for encapsulated 1.8 nm GNP in Bfr.  
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The encapsulated 5 nm GNPs were analyzed under TEM using molybdic 
acid after being separated on GE SephacrylTM S-300 HR resin. The 
encapsulated 5 nm GNP images exhibited a clear protein coat fully covering the 
surface (Figure 2.31). In addition, all the GNPs present in these images were 
clearly encapsulated. When compared, the width of the protein coat matched the 
width of the measured shell of apo-Bfr. Analysis with the EMAN2 program was 
performed as before, and it was possible to derive an averaged measurement for 
the radius of the host-guest complex (Figure 2.32). Slight increases in diameter 
were observed with an increase of approximately 2-3 nm based on the averaged 
image. Such increases suggested conformational changes to the protein coat 
structure to accommodate this large guest molecule. Stable conformational 
changes appeared to be allowable as a result of the compensatory number of 
multiple affinity interactions between host and guest. For the SF encapsulation 
study tetrameric SF had a maximum of four possible affinity interactions, 
whereas the gold nanoparticle had several NTA affinity ligands. The GNP was 5 
nm in diameter with an approximate 1.5 nm extension in thickness of the shell 
due to the addition of a polymer terminated with NTA linkers. Based on the 
diameter of a sphere of 5 nm the absolute maximum number of affinity tags can 
be approximated to 130. It was likely much lower than 130, but this still gives a 
sense of the difference in number of affinity interaction between SF and 5 nm 
GNP.  
To address the question of why the 1.8 nm GNP was less successful than 
the 5 nm GNP for encapsulation within Bfr, it could be theorized that the GNP 
was acting more as a scaffold for Bfr rather than a passive guest. The 5 nm GNP 
was of a similar size and shape to the native interior volume of Bfr, and could 
have built the Bfr shell around it. Whereas the 1.8 nm GNP was significantly 
smaller than the internal volume of Bfr, and may have not been an ideal 
template to complement the native self-assembly of Bfr. In the case of the 1.8 
nm GNP, fewer affinity ligands may have been more ideal. Many affinity 
ligands on 1.8 nm GNP may have dominated the interaction between GNP and 
Bfr over Bfr-Bfr subunits. If a single affinity ligand existed between 1.8 nm 
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GNPs and Bfr, self-assembly of Bfr may have instead been dominated by the 
native interaction energy between subunits. Future nanoparticle encapsulation 
should take into consideration this effect in choosing the size of guest and the 
number of affinity interactions it possesses (Figure 2.33). 
 
Figure 2.31: TEM images of free and encapsulated 5 nm GNP in 100% His6-tag Bfr. A WT Bfr 
negative control (A) revealed 5 nm GNPs not encapsulated, as highlighted in the insert. A thin 
polymer coating of an approximate width of 1.5 nm. The 5 nm GNP was encapsulated within 100% 
His6-tag Bfr, as was evidenced by the extremely electron dense interior within Bfr, and the width of 
the protein shell. The protein shell was measured as approximately 3.7 nm, similar to the width of 
native Bfr observed with TEM.    
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Figure 2.32: Single particle analysis of 5 nm GNP encapsulated within 100% His6-tag Bfr. The 
reference free class of these images generated a particle with sizes slightly larger than previously 
seen. The interior diameter appeared to be closer to the size of the GNP, and the exterior diameter 
had grown by two nanometers to approximately 14 nm. 
 
Figure 2.33: Geometrical factors and the number of affinity interactions determined the success and 
failure of 5 nm and 1.8 nm GNP encapsulation. By having multiple affinity ligands on the 1.8 nm 
GNP it did not act as an ideal scaffold for Bfr to build onto (A). The 5 nm GNP, however, matched 
the native internal size of Bfr, appropriately, and thus was a good scaffold to build Bfr onto (B). If 
instead only one affinity interaction was available between Bfr and the 1.8 nm GNP, then the self-
assembly of Bfr might not be disrupted by competing affinity interactions. 
 
A B C 
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2.3.5. Structural Investigation of the Dimer-24mer Equilibrium, and 
the Significance of Heme 
Investigation into the self-assembly of 24mer Bfr was an ongoing side 
project during the fulfilment of this M.Sc. degree. As has been stated, Bfr and 
ferritins have been documented as existing in equilibrium between two states: a 
fully formed 24mer, and a dimer. Not much is known of the intermediate forms 
occupied between these two states. In the process of performing experiments 
and controls, it was noted that in both size exclusion chromatography and native 
PAGE the presence of heme in the Bfr structure increased the population of 
24mer (Figure 2.34). Heme alone seemed to be contributing to the stabilization 
of the 24mer structure. This was curious because heme is found at the interface 
between dimers. It was not expected that a missing element between dimers 
would strengthen the full 24mer species. Differential scanning calorimetry was 
attempted to evaluate the claim that the complex was strengthened by the 
presence of heme. MS was approached, as well, as a method to examine this 
claim, both of which were unsuccessful. The data from the size exclusion and 
native PAGE suggest that heme strengthened the 24mer state, which would 
make heme an important structural factor for Bfr.  
 
Figure 2.34 : Analysis of the effects of heme with respect to the equilibrium of Bfr between dimer 
and 24mer states. Bfr with and without heme was run on a GE SephacrylTM S-300 HR size exclusion 
resin (A). When the heme containing Bfr was run on a native PAGE (B) it would run with a high 
molecular weight band and low molecular weight band, whereas the Bfr without heme ran as only 
one lower molecular weight band.   
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Differential scanning calorimetry was performed on Bfr, but a distinct transition 
temperature was undetectable. This was not wholly unexpected since there 
would be a litany of individual unfolding events taking place at varied 
temperatures. This likely helped to obscure the overall reading, and little 
information was gathered from this technique. MS was explored as well to try 
and utilize some previously derived experimental conditions for observing 
native conformations of proteins.166 Proteins were suspended in 200 and 20 mM 
ammonium acetate solutions before running on an ESI-QTOF MS. His6-tag Bfr 
with heme re-incorporated was run in these native conditions. Some success 
was made in generating lower charge state peaks in the spectrum (Figure 2.35). 
Low charge state ions are expected for the native structures of proteins in the 
gas phase.180 There was a clear shift to these ions from the typical spectrum 
generated. The spectrum range would likely have to be extended greatly to 
accommodate the large mass of multimeric proteins. It was not possible to scan 
with the same range that other experimenters have used, reaching a maximum 
range of 4000 m/z, which may have not have been enough to capture larger 
complexes.166 In addition, the nanospray ESI-Q-TOF was not modified in the 
exact fashion as in these previous experiments.166 However, these initial results 
suggested that it is highly likely to examine Bfr in a non-denatured form with 
MS.167 Unfortunately, the instrument used to run these experiments was under 
repairs shortly after obtaining these results, and follow up experiments could not 
be performed.   
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Figure 2.35: Native protein MS trials using heme containing Bfr. Bfr with heme was exchanged into 
a 20 mM ammonium acetate solution and run on a nanospray ESI-QTOF mass spectrometer (A). 
When run in denaturing conditions the spectrum contained higher charge state ions, as was usual 
(B). When the native spectrum was deconvoluted it revealed a protein mass of 19560 Da, as was 
expected for the monomeric protein.  
2.3.6. Conclusion 
By demonstrating the encapsulation of protein and nanoparticle guest 
molecules Bfr was evaluated as a platform to encapsulate foreign guests. 
Through chromatographic, fluorescent, and TEM, SF was able to be 
characterized as encapsulated within Bfr. The 1.8 nm and 5 nm GNPs were 
evaluated, and only the 5 nm GNP was able to be encapsulated, as confirmed 
with chromatography and TEM. It was curious that the 1.8 nm GNP did not 
encapsulate within Bfr, whereas the much larger 5 nm GNP was encapsulated to 
a high degree. It has been hypothesized that the reason for this discrepancy 
might be due to both the size and the number of affinity interactions. The 5 nm 
GNP complimented the interior diameter of Bfr, and may have acted as a 
scaffold. The 1.8 nm GNP too acted as a scaffold, but with disproportionate 
geometry to the Bfr interior. If the 1.8 nm GNP could be synthesized with one 
or two affinity ligands it might act less like a scaffold. This balance between 
size and number of affinity ligands displayed will play an integral aspect in the 
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decision for future guests. Larger guests that may cause minor perturbations in 
the native structure of Bfr may be compensated for by numerous affinity 
interactions. With both SF and the 5 nm GNP it was demonstrated that the 
affinity interaction was critical for the specific encapsulation of the guest 
particle within the host Bfr. Preliminary results were also presented that suggest 
that the heme cofactor was important for the formation of the 24mer complex. 
This was shown with size exclusion and with native PAGE. The factors that 
heme had on the formation of 24mer Bfr are unknown, but the evidence does 
suggest that it contributes to a shift in the equilibrium between the dimer and 
24mer state.   
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3. Chapter 3: Cofactor Modification  
3.1. Introduction  
In the ferritin superfamily of proteins, Bfr is the only family member that 
contains heme cofactors. Heme is protoporphyrin IX, which is protoporphyrin 
with an iron atom in the centre of the porphyrin ring. In the context of Bfr, the 
heme cofactors are coordinated by two methionines, M52, from separate 
protomers (Figure 3.1). As is observed, the heme binding pocket is on the inner 
face of Bfr with propionate groups exposed and pointing to the inside of the 
cage protein. It was hypothesized that by modifying the propionate groups little 
would be altered in hemes ability to be coordinated by Bfr. Heme propionate 
groups exposed in this nature provided a unique opportunity for adding an array 
of functionalities and ligands to heme, and thus to Bfr. In addition, increased 
complexity of heme labelling could be obtained by individually modifying 
propionate groups98 (Figure 3.2). These factors make heme an important and 
ideal cofactor to explore for further development of Bfr as a platform for 
bionanotechnology.    
 
 
Figure 3.1: A crystallographic image of the heme binding pocket of Bfr displaying the heme 
propionates facing the interior space, and the C and N termini are shown facing the interior and 
exterior, respectively (A). The heme binding pocket (B) clearly is on the interior face, and the 
propionate groups are solvent exposed (C).   
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Figure 3.2: Potential labels for heme propionate groups (A). Alternatively labeled hemes could be 
mixed within the same Bfr 24mer to add additional complexity (B). Alternatively, two alternate 
labels could also be combined on a single heme (C). 
In this chapter heme modification of the propionate groups will be 
explored with a variety of functionalities. Heme modification was primarily 
examined with fluorescent labels to develop a proof of principle for the ability 
to label heme with large fluorescent molecules and then incorporate them into 
Bfr. Modifications of the propionate groups of heme have been made and 
successfully incorporated back into myoglobin in previous studies95, and so 
there is precedence for functionalizing heme in this way.  The fluorophores 
explored were Lucifer yellow (LY), a coumarin derivative (DCCH), and two 
fluorescein derivatives (FSTC, AAF) (Figure 3.3). Two non-fluorescent 
molecules were also labelled onto heme: N-butylamine (NBA) and an NTA 
derivative (Lysine-NTA) (Figure 3.3).  
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Figure 3.3: Structures of heme (A), NHS (B), NBA (C), LY (D), DCCH (E), FSTC (F), AAF (G), and 
lysine-NTA (H).    
 The reaction used to label heme propionate groups followed an 
activation scheme where the propionates were reacted with a carbodiimide and 
an N-hydroxysuccinimide (NHS) producing heme-NHS. Heme-NHS served as 
a semi-stable intermediate, which could be used directly to label heme with 
molecules containing primary amines or hydrazides (Figure 3.4). In earlier work 
performed by Denise Lieuson of the Honek laboratory, hydroxybenzotriazole 
was used in combination with a carbodiimide, but eventually the heme-NHS 
preparation method was adopted for all heme labelling experiments. Heme was 
modified out of the protein environment, which was an advantage of this 
process, and then reinserted into the protein architecture. This allowed for 
stringent conditions to be used without the associated risks of damage to the 
protein. This chapter will explore the labelling, purification, and incorporation 
of modified heme (mod-hemes) into His6-tag Bfr.  
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Figure 3.4: Reaction mechanism for the synthesis of heme-NHS using a polystyrene linked 
carbodiimide. 
3.2. Materials and Methods 
All materials and methods for this section of the thesis are listed below 
otherwise they have been listed in chapter 2. 
3.2.1. Materials 
Hemin (Sigma-Aldrich, Buchs, Switzerland), PS-carbodiimide (Biotage, 
Hengoed, United Kingdom), N-Hydroxysuccinimide (1-Hydroxy-2,5-
pyrrolidinedione) (Sigma-Aldrich, Louis, MO, USA), 5-
(Aminoacetamido)fluorescein (fluoresceinyl glycine amide) (Molecular 
Probes® Life Technologies, Eugene, OR, USA), 7-Diethylaminocoumarin 
(Molecular Probes® Life Technologies, Eugene, OR, USA), Nα,Nα-
Bis(carboxymethyl)-L-lysine (Sigma-Aldrich, Buchs, Switzerland), N-
butylamine (Spruce Street, Saint Louis, MO, USA), Fluorescein-5-
Thiosemicarbazide (Molecular Probes® Life Technologies, Eugene, OR, USA), 
Lucifer yellow ethylenediamine (Molecular Probes® Life Technologies, 
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Eugene, OR, USA), Biotage® KP-C18-HS SNAP column (Charlotte, NC 28269 
U.S.A), GE SephadexTM LH-20 (GE Life Sciences Quebec, Canada), GE 
SephadexTM G-25 Fine (GE Life Sciences Quebec, Canada), Corning® half-
area black 96 well microplate (Corning®, Lowell, MA, USA), 
Dimethylformamaide from a Sure-SealTM bottle was stored over dry 4 Å 
molecular sieves (Sigma-Aldrich, Sheboygan Falls, WI, USA), and Dimethyl 
Sulfoxide from a Sure-SealTM bottle was stored over dry 4 Å molecular sieves 
(Sigma-Aldrich, Sheboygan Falls, WI, USA) were used for synthesis and 
purification.  
3.2.2. Safety 
All solvents were handled with appropriate glove wear, laboratory coats, 
googles, and in a fume hood. Chromatography using solvents was performed in 
a fume hood, and silica resins and TLC plates were disposed of correctly 
through the hazardous waste management facility. All biological substances, 
such as bacterial cultures, were handled in accordance to biological level 1 
safety environments and either autoclaved or bleached overnight before 
disposed in a biohazardous waste container.    
3.2.3. Heme Analogs 
 Heme-NHS was synthesized by adding hemin 
((Chloro(protoporphyrin)iron(III); 200 mg,  0.307 mmols) and PS-carbodiimide 
(954mg, 2.8 equiv., 1.3 mmol/g) to 3.2 ml of anhydrous DMF with stirring at 23 
°C for 10 minutes. NHS (88 mg, 2.5 equiv., 0.76 mmol) was added to this 
solution and stirred at 100 °C for an hour in a Biotage® Initiator microwave 
synthesizer (Scheme 1). After an hour, the solution was allowed to come to 
room temperature and the PS-carbodiimide was removed by running the 
solution through a column with glass wool packed at the bottom. The flow 
through solution was precipitated into 10 times the volume of chilled 
isopropanol and centrifuged at 5800 rpm for 10 minutes in a VWR clinical 100 
centrifuge. The pellet was collected, dried in vacuo, and stored away from light 
exposure at -20 °C. The reaction was not further purified, which was performed 
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after downstream reactions. On silica plate thin layer chromatography (TLC) in 
dichloromethane:methanol 9:1 mobile phase, the heme-NHS product had two Rf 
values of 0.62 and 0.75.   
Scheme 1: Heme-NHS synthesis from heme activated with PS-carbodiimide and reacted with NHS 
 
3.2.4. Reactions of Heme-NHS with NBA, LY, FSTC, Lysine-NTA, AAF, 
and DCCH 
 Heme-NBA was synthesized by mixing heme-NHS (3.4 mg, 4.2 µmol) 
and NBA (1.2 mg, 16 μmol, 4 equiv.) and stirring in 500 µl of anhydrous DMF 
for 40 minutes at 100 °C in a Biotage® Initiator microwave synthesizer 
(Scheme 2). Heme-LY was synthesized by mixing heme-NHS (4.3 mg, 5.3 
µmol) and LY (6.2 mg, 11.9 µmol, 2.5 equiv.) together in 500 µl of anhydrous 
DMF and water (1:1 ratio) for 45 minutes at 100 °C in a Biotage® Initiator 
microwave synthesizer. Heme-FSTC was synthesized by mixing heme-NHS 
(1.12 mg, 1.38 µmol) and FSTC (3.09 mg, 7.33 µmol, 5 equiv.) in 500 µl of 
anhydrous DMF for 6 hours at 50 °C in a Biotage® Initiator microwave 
synthesizer. Lysine-NTA was dissolved in anhydrous DMSO by vigorously 
mixing at 23 °C to make 1 ml of a 10 mg/ml solution. Heme-lysine-NTA was 
synthesized by mixing heme-NHS (1 mg, 1.23 µmol) with DMSO dissolved 
lysine-NTA (1 mg, 3.81 µmol, 3 equiv.) in 500 µl of anhydrous DMF for 6 
hours at 80 °C in a Biotage® Initiator microwave synthesizer. Heme-DCCH 
was synthesized by mixing heme-NHS (5.5 mg, 6.79 µmol) and 500 µl of a 10 
mg/ml DMF solution of DCCH (4.67 mg, 16.97 µmol, 2.5 equiv.) into a total 
volume of 1500 µl of anhydrous DMF stirred at 50 °C for 6 hours in a Biotage® 
Initiator microwave synthesizer. Unreacted activated mono heme-DCCH was 
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reacted to completion by the addition of more free DCCH (1.1 mg, 4.07 µmol, 
0.6 equiv.).Heme-AAF was synthesized by mixing heme-NHS (2.0 mg, 2.47 
µmol) and 500 µl of a 5mg/ml solution of AAF (2.5 mg, 6.17 µmol, 2.5 equiv.) 
to 550 µl of DMF and stirred at 50 °C for 6 hours in a Biotage® Initiator 
microwave synthesizer.  
Scheme 2: General reaction scheme for heme propionate group labelling.  
 
3.2.5. Purification of Modified-heme products 
 Bis heme-DCCH was purified on a Biotage® KP-C18-HS SNAP 
column with a Biotage® Isolera chromatography system. Reaction product was 
diluted from 500-1000 µl into 100x MeCN with 2% glacial acetic acid. This 
was then added to a Biotage® KP-C18-HS samplet (3 g) where a tight brown 
band would form at the top of the samplet. Once dry, the samplet was added to a 
KP-C18-HS column (30 g resin) that had been equilibrated with 100 ml of 7 
mM potassium phosphate dibasic buffer at pH 7.0. The samplet was then 
washed with 50 ml of the same phosphate buffer. Two gradients were used, the 
first going from 100% phosphate buffer to 100% MeCN in 300 ml. The second 
gradient went from 100% MeCN to 50% MeOH in 1240 ml, and finally to 
100% MeOH in 100 ml. Heme-AAF was purified using a GE SephadexTM LH-
20 resin (8.6 ml of resin, column dimensions of 10 mm x 110 mm). The running 
solution was 100 mM potassium phosphate dibasic buffer at pH 8.0. Heme-
AAF reaction product was added in 100-500 µl injection volumes and run at a 
flow rate of 40 ml/hr with fractions collected at 2 minute intervals. The first 
eluted peak was collected and used directly for incorporation within Bfr. 
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3.2.6. Insertion of Mod-heme into Bfr    
 Bis heme-DCCH in DMF (3.5x10-8 mol, 1.0 equiv.) was added to His6-
tag Bfr (7.0x10-8 mol) and placed in a water bath at 80 °C for 10 minutes 
buffered with 0.2 M MES and 1.0 M NaCl at pH 6.5, as was outlined in 
previous research139. After 10 minutes of incubation the sample was left to cool 
to 23 °C on the bench. Unincorporated bis heme-DCCH was separated from 
incorporated bis heme-DCCH on a GE SephadexTM G-25 Fine column using a 
buffered running solution of 50 mM Tris and 100 mM NaCl at pH 8.0. Heme-
AAF (2.6x10-8 mol, 2 equiv.) was taken directly from the GE SephadexTM LH-
20 column and mixed with His6-tag Bfr (2.6x10-8 mol) at 80 °C for 10 minutes, 
and then cooled to 23 °C on the laboratory bench, as before. Heme-AAF 
incorporated in Bfr was separated on a GE SephadexTM G-25 Fine column from 
unincorporated heme-AAF using a buffered running solution of 50 mM Tris and 
100 mM NaCl buffer at pH 8.0. 
3.2.7. MS Experimentation   
Crude reaction samples were prepared by taking 5 µl of a 16 mM crude 
reaction and diluting into 50 µl of 1:1 MeCN:H2O with 0.2% formic acid, and 
then taking 5 µl of that dilution and further diluting into 50 µl of the same 
solution. This was run on a Waters Micromass MassLynx nanospray 
electrospray ionization quadrupole time of flight mass spectrometer. MS/MS 
experiments were performed by selecting the ion of interest and increasing the 
collision energy to 40-60 eV.   
3.2.8. Anisotropy Measurements 
 Anisotropy was measured on a Molecular Devices Spectramax 
M5 fluorescence plate reader using the pre-set basic anisotropy protocol. 
Sucrose from a 60% stock in 50 mM Tris, 100 mM NaCl buffer at pH 8.0 was 
added in 3% increments to a final concentration of 30% sucrose to the mod-
heme incorporated Bfr in a Corning® half-area black flatbottom 96 well 
microplate with 50 µl of sample in each well and a 50 µl buffer blank well, 
which also had sucrose added to it during the reading. 
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3.3. Results and Discussion 
3.3.1. Heme Preparation and Modification 
3.3.1.1. Heme Activation with NHS 
The first work with heme was performed by an undergraduate student in the 
Honek laboratory, Denise Lieuson. She had started the work with heme 
labelling, and successfully developed a method for the synthesis of heme-NHS, 
labelling of heme with N-butylamine (NBA) and labelling with Lucifer yellow, 
but was unable to purify any of these products. This work laid the basis for 
future synthesis reactions, and to best document the progress of the mod-heme 
project, a terse overview of this previous work will be highlighted here for the 
sake of consistency. 
Denise Lieuson worked on several methodologies with carbodiimides to try 
and activate the propionate groups for functionalization with amine and 
hydrazide containing labels. Heme in its solid form is hemin, which is identical 
to heme with the exception that a chloride coordinates the heme iron, and is 
only soluble in dimethylformamide (DMF). Therefore all reactions were carried 
out in anhydrous DMF. The method that was eventually developed and used for 
much of the labelling experimentation to follow was mixing of hemin with a 
polystyrene bead linked carbodiimide (PS-C) (2.8 equiv.) and NHS (2.5 equiv.) 
in DMF. The product, Heme-NHS, would form both mono and bis heme-NHS 
products, quantities of which varied between reactions (Figure 3.5). The mono 
heme-NHS product was not separated from the bis product because purification 
would be performed downstream after functionalizing heme with desired labels. 
Heme appeared to react until completion, as monitored by MS with no 
detectable presence of free heme, and formed largely the bis heme-NHS 
product. Evaluation of the ratios of products by MS required the assumption 
that the mono and bis products would ionize to the same degree without 
supressing ionization of the other. Since these were highly similar molecules it 
was perceived as a qualitative method to analyse reaction completion and 
evaluate mono and bis product ratios qualitatively.  
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Figure 3.5: Three alternate reactions of heme with NHS (A, B, and C) demonstrating the varying 
quantities of mono and bis substituted heme-NHS. The mono heme-NHS had a calculated molar 
mass of 713.56 g/mol, and the bis heme-NHS had a calculated molar mass of 810.63 g/mol. 
Structures are also displayed (D). 
3.3.2. Heme Modification with Functional Labels 
3.3.2.1. Heme Reaction with N-Butylamine  
The first attempted label was a small ligand, N-butylamine (NBA), which 
established the ability to label heme with a simple ligand. Heme-NHS was 
mixed with NBA in anhydrous DMF for 40 minutes at 100 °C. This resulted in 
the formation of predominantly bis heme-NBA, with some of the mono labelled 
heme (Figure 3.6). This established that heme was able to be labelled with a 
simple molecule containing an amine using this particular reaction scheme. The 
labelled heme produced was primarily the bis product, this was likely due to the 
size of the ligand, having little steric hinderance on bis product formation. As 
will be discussed, the larger fluorescent ligands showed less bis product 
formation than the smaller NBA. Denise Lieuson, with my supervision, 
attempted to incorporate this modified heme into His6-tag Bfr. The Heme-NBA 
product was soluble in DMSO, which was used to incorporate into His6-tag Bfr. 
DMSO was not an ideal solvent since it was observed to cause some 
precipitation of Bfr. This likely led to the low levels of heme within His6-tag 
Bfr. A spectral shift in the Soret peak of heme to 418 nm, indicative of heme 
incorporation into His6-tag Bfr was observed. However, this was the only 
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evidence of re-insertion, and no further proof was obtained since this molecule 
was not easily distinguished within the protein milieu.  
 
Figure 3.6: The heme-NHS reaction with NBA label, a small alkane containing an amine, monitored 
with MS. This small label was substituted primarily as the bis product, which had a calculated molar 
mass of 726.73 g/mol. The mono could be observed as a small peak with a calculated molar mass of 
671.61 g/mol. The full spectrum (A) and an enhanced region of the spectrum highlighted the mono 
and bis heme-NBA peaks (B), with the structures of the mod-heme (C).   
3.3.2.2. Heme Reaction with Lucifer Yellow 
By labelling heme with a fluorescent agent it would be possible to 
characterize the incorporation of mod-heme in Bfr, and any effects that might 
arise with localization of multiple fluorophores within the restricted space of 
Bfr. Lucifer yellow (LY) was the first fluorophore chosen to explore for 
labelling of heme (Figure 3.3). It was chosen because of its water solubility, 
which was expected to improve solubility of the final product. Increased 
aqueous solubility of product would likely enhance the ease of mixing and 
incorporation into Bfr. This dye was non-soluble in DMF, however, which was 
the crux of some of the issues associated with synthesizing heme-LY in high 
quantities. Upon performing these reactions there was clearly less heme-LY 
present (Figure 3.7). Unfortunately, this product was never produced in high 
enough quantities for incorporation into Bfr. In the mass spectrum there was a 
second peak observed, which had a mass of 1038 g/mol, 27 mass units higher 
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than the expected mono product. This was later determined to likely be the 
result of a porphyrin modification from the hydrazide functionality of LY, 
explained below. The issue of LY solubility in DMF resulted in synthesis 
issues, which was also observed to be somewhat limiting with the synthesis of 
heme-lysine-NTA. As a consequence of the poor reactant solvent 
compatibilities experienced here two alternative dyes were explored.  
 
Figure 3.7: The synthesis of heme-LY as monitored by MS. Here the full spectrum (A) showed that 
the mono heme-LY peak was almost within the background, and only upon closer examination of 
the expected region of the spectra where the heme-LY product would lie (B, C) can one observe the 
mono heme-LY product with a molar mass 1013.8 g/mol, which was two mass units higher than the 
observed mass. A second product peak 27 mass units higher than the expected mono heme-LY mass 
was observed. The labeled mod-heme structure is displayed as well (D). 
3.3.2.3. Heme Reaction with 7-Diethylaminocoumarin-3-
Carboxylic Acid, Hydrazide  
A coumarin derivative, 7-Diethylaminocoumarin-3-Carboxylic Acid, 
Hydrazide (DCCH) (Figure 3.3), was used as a proof of principle to show 
that heme could be fluorescently labelled and then incorporated back into 
His6-tag Bfr. This dye was chosen because it was soluble in DMF, and 
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therefore would remediate the suspected solvent solubility issues 
encountered with LY. The excitation and emission wavelengths for DCCH 
in MeCN are 420 nm, and 468 nm, respectively.  
The reaction with heme proceeded similarly to the previous reactions 
with NBA and LY, where heme-NHS was mixed in anhydrous DMF with 
DCCH. Reaction completion was monitored with MS, as before (Figure 
3.8). There were three product species observed in the mass spectrum of the 
reaction mixture after synthesis: an 873.77, 970.84, and 1131.03 g/mol peak 
corresponding to the mono, mono activated, and bis labelled heme DCCH, 
respectively. The mono activated heme contained one dye and one NHS 
group, which was able to be further reacted to bis labelled heme by the 
addition of free DCCH until all mono activated heme was converted to bis 
heme-DCCH (Figure 3.9).  
  
Figure 3.8: Synthesis of heme-DCCH with the full spectrum (A), and an enhanced area of the 
spectrum showed the ions of interest (B). The mono heme-DCCH had a molar mass of 873.77 
g/mol, and the bis heme-DCCH had a molar mass of 1131.03 g/mol. 
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Figure 3.9: Addition of free DCCH dye reacted with mono-activated heme-DCCH at 0 hours 
(A), overnight (B), and after three days (C). The disappearance of the mono-activated peak can 
been observed as time progressed.   
 In addition to the expected labelled peaks of heme there was an 
additional peak observed that was slightly larger than the mono heme-
DCCH. This peak was 900 mass units, which was an increase of 27 mass 
units from the mono heme-DCCH. To explore the potential of this ion 
belonging to a heme side reaction, MS/MS experiments were performed 
(Figure 3.10). When the 900 peak was analyzed in MS/MS with a collision 
energy of 50 eV the peak fragmented to a 882 peak, signifying the loss of 
water from the parent 900 peak, and thus that the second carboxylic acid on 
heme was unmodified. This same 18 mass unit decrease was observed for 
the 873 peak during MS/MS experiments. This indicated that the 
modification could have been an addition to the porphyrin ring. 
Confirmation of this was seen with the lack of a 557 peak, which was 
observed when the mono heme DCCH was fragmented. This 557 peak was 
also seen with the heme fragmentation, but was not observed with the 900 
peak. There was, however, a 584 peak, which was 27 mass units larger than 
the 557 peak observed with both heme and mono heme-DCCH fragments. 
This further confirmed that the likely modification was on the porphyrin 
ring. The potential source of this modification was explored. In the reaction 
mixture there were few components that could have contributed to this side 
product: heme itself, the DCCH dye, the DMF dolvent, or liberated NHS. It 
was noticed that the expected mass for DCCH, 275, was not observed in the 
spectrum after the reaction, and instead a 244 peak was observed. This peak 
was 32 mass units less than the expect mass, which was possibly a result of 
the loss of the hydrazide functionality (Figure 3.11). The hypothesis of 
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hydrazide loss was bolstered by results in the FSTC work, discussed below. 
The mechanism and exact nature of this modification was not further 
explored because it was neither the main interest of this research nor critical 
for the continuation of this research. Exploration of optimal conditions for 
the synthesis of bis heme-DCCH and lower quantities of the heme side 
product were explored by examining various reaction temperatures (Figure 
3.12). The optimal conditions with the highest bis heme-DCCH and lowest 
heme side product were determined to be 50 °C. This temperature was used 
throughout the rest of the synthesis to attempt to limit the amount of side 
product formation. Vinyl side reaction was likely since it has been shown in 
nature that the vinyl groups are reactive towards amino acids.181  
 
Figure 3.10: MS/MS experiments with the 900 peak (A), the mono heme-DCCH 873 peak (B), 
and with heme 616 peak (C). Both the 900 peak and mono heme-DCCH 873 peak showed an 18 
mass unit loss, which is typical of water loss from carboxylic acids. This indicated that both ions 
likely contained a free carboxylic acid functionality. Both mono heme-DCCH and heme showed 
a 557 fragment peak, which corresponded to the loss of four oxygens from the protoporphyrin 
propionate functionalities. The 900 peak had a fragment peak 27 mass units higher than this, 
which indicated that there was likely a modification to the porphyrin ring of mono heme-
DCCH. 
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Figure 3.11: Free DCCH fragmented by MS/MS showing a 244 ion peak, which was seen in the 
spectra from reacted DCCH instead of the expected 276 ion, a loss of 32 mass units. 
 
Figure 3.12: Temperature trials with heme-DCCH reaction using temperature of 40 (A), 45 (B), 
50 (C), 55 (D), 60 (E), 65  (F), 70 (G), and 80 °C (H). The 80 °C reaction trial had a significant 
amount of the side reaction 900 peak. The optimal condition chosen was 50 °C, which seemed to 
have the least amount of the side reaction peak, and the most bis mod-heme. 
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3.3.2.4. Heme Reaction with Fluorescein-5-
Thiosemicarbazide 
A fluorescein derivative, Fluorescein-5-Thiosemicarbazide (FSTC) 
was also explored as a fluorescent molecule to functionalize heme (Figure 
3.3). FSTC, along with many fluorescein derivatives, are ideal candidates 
because of the dual solubility in both DMF and H2O when the pH is above 
pH 6. FSTC has a molecular weight of 421 Da, and excitation and emission 
wavelengths in water of 492 nm and 516 nm, respectively. Synthesis of 
heme-FSTC proceeded in the same fashion as with the synthesis of the 
previous mod-hemes. Heme-NHS was mixed in anhydrous DMF in the 
presence of FSTC. Unlike the DCCH reactions, there was no product 
observed. All the Heme-NHS remained unreacted, and it seemed that most 
of the FSTC had disappeared (Figure 3.13). Initially, this was unexpected, 
but after more careful consideration a pattern emerged that was similar to 
what was observed with DCCH synthesis. There was a 390 Da peak 
associated with the loss of 32 Da from free FSTC observed in the spectrum, 
as was seen with DCCH reactions. When the free FSTC was run there was 
no 390 Da peak, and so the free FSTC was fragmented using MS/MS 
(Figure 3.14). A 390 fragment arose from the MS/MS of the 422 FSTC 
peak. This was likely a result of loss of the hydrazine on FSTC rather than 
the sulfur from the thioketone since it was the same mass loss seen with 
DCCH. FSTC seemed to lose the hydrazine more vigorously than DCCH, 
which may be a result of the slight difference in chemistry since DCCH 
contained a ketone rather than a thioketone. This rapid loss of hydrazine 
resulted in none of the heme-NHS being labelled. Closer examination of the 
reaction spectra revealed that FSTC was modifying heme in the same way 
that DCCH did. A peak corresponding to mono heme-NHS with a 27 mass 
unit increase was observed (Figure 3.15). This side reaction must have been 
of the same mechanism as previously seen with DCCH, but fast enough 
such that no desired product could be formed. A second fluorescein 
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derivative was chosen to label heme-NHS with, which lacked a hydrazide 
and thioketone.   
 
 
 
Figure 3.13: Initial reaction of FSTC with heme-NHS (A), and enhancing the area of spectra 
where there appeared to be the unreacted mono heme-NHS (713) and the bis heme-NHS (810) 
(B). The structure of the mod-heme is displayed as well (C). 
  
Figure 3.14: Free FSTC fragmented with MS/MS showed a 390 peak, which corresponded with 
the loss of 32 mass units from the original mass. This was similar to the mass loss of 32 Da from 
the fragmented DCCH dye. 
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Figure 3.15: The side reaction to the mono heme-NHS reactionshowing a shift in mass of 27 Da 
was observed as a peak at 740. This was likely a result of the same chemistry seen with the 
DCCH reactions. 
3.3.2.5. Heme Reaction with AAF 
After lackluster synthetic results with FSTC, a new fluorescein 
derivative, 5-(Aminoacetamido)Fluorescein (AAF), with the same physical 
properties as FSTC was purchased (Figure 3.3). AAF has a molecular 
weight of 404 Da, and excitation and emission wavelengths in water of 491 
and 515 nm, respectively. This new fluorescent molecule lacked the 
hydrazide functionality that was previously found in both DCCH and FSTC. 
AAF was added to heme-NHS in the same fashion as previously described 
which included mixing heme-NHS in anhydrous DMF with AAF. The 
resulting reaction showed that there was a mono, mono-activated, and bis 
substituted heme-AAF after reaction (Figure 3.16). Addition of additional 
AAF converted the remaining mono-activated heme-AAF to bis heme-AAF, 
and therefore the reaction proceeded to completion. With AAF there was no 
observed degradation of mod-heme or of the unreacted AAF. These 
synthesized products were later purified and then incorporated into Bfr.  
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Figure 3.16: Synthesis of heme-AAF (A and B) showing the expected masses for mono, mono-
activated, and bis products. There was no heme porphyrin side reaction, as observed before, 
and the AAF fluorophore did not degrade. The Structure is displayed as well (C). 
3.3.2.6. Heme Reaction with Lysine-NTA 
In addition to the fluorescent labelling of heme, an affinity ligand was 
explored to further functionalize the heme cofactor, Nα,Nα-
Bis(carboxymethyl)-L-lysine (lysine-NTA) (Figure 3.3). By generating this 
functional group on heme it would allow for the reversal of the host-guest 
affinity interaction that was explored in chapter two. Lystine-NTA was not 
soluble in DMF, but was partially soluble in DMSO. Lysine-NTA was first 
dissolved in anhydrous DMSO at a concentration of 10 mg/ml, which was 
then added to a solution of heme-NHS in DMF. The progress of the reaction 
was monitored by MS, as previously (Figure 3.17). The expected mass for 
the mono substituted heme-lysine-NTA was observed at 860 Da. There was 
also some free heme, 616 Da, but no side reactions with heme, nor any 
degradation of free lysine-NTA. The presence of free heme was not 
observed for any of the previous reactions with fluorophores, which might 
have been due to the presence of trace water in the reaction solution. Trace 
water might have hydrolyzed the heme-NHS to produce heme. 
Alternatively, the remaining stock of Heme-NHS used may have degraded 
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with time. Although mono heme-lysine-NTA was demonstrated to be 
synthesized, continued work with synthesis, purification and incorporation 
of this mod-heme are required. Due to the fact that lysine-NTA is a highly 
aqueous soluble molecule it should increase the solubility of the heme-
lysine-NTA product. This should thus improve the incorporation into Bfr, as 
was seen with heme-AAF incorporation in Bfr outlined below.   
 
Figure 3.17: Synthesis of heme-lysine-NTA (A and B) with the expected mass of 860 g/mol for 
the mono heme-lysine-NTA product, but not the bis modified product. There appeared to be no 
heme side reaction being formed, and the unreacted lysine-NTA appeared to not be degraded. 
The structure of the mod-heme is displayed as well (C).   
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3.3.3. Mod-Heme Purification  
3.3.3.1. Heme-DCCH Purification 
The purification of bis heme-DCCH from the reactants and mono heme-
DCCH product required exploration of many resin types, and many conditions. 
As it was found, it was less challenging to separate mod-heme from reactants, 
but much more challenging to separate the highly similar mono heme-DCCH 
from the bis heme-DCCH, which resulted in extremely low yields. The first 
column used was a GE LH-20 resin, which was described as useful for natural 
product separation by size, and was tolerant to almost all solvent types. This 
made LH-20 seem like an ideal candidate for the purification of bis heme-
DCCH. The use of this column resulted in the partial separation of mono from 
bis heme-DCCH, but was unable to completely purify the bis heme-DCCH 
product (Figure 3.18). After several attempts to separate mono from bis product 
on LH-20 other resin types were explored.  
 
Figure 3.18: Bis heme-DCCH purification on a GE SephadexTM LH-20 resin. Fraction 67-79 (A) and 
86-end (B) show a shift in the ratios of mono heme-DCCH to bis heme-DCCH towards more bis 
heme-DCCH. Despite many trials and conditions these two products could not be fully separated 
from each other. The elution profile was monitored by examining the wavelengths at 380 and 420 
nm, corresponding to the heme absorption and DCCH absorption maxima, respectively (C). 
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 A series of macroreticular anion exchangers were used to try and bind 
the available carboxylic acid found on the mono heme-DCCH product in an 
attempt to purify bis heme-DCCH, which lacked any carboxylic acid 
functionality. Unfortunately, these resins were unable to make such separations. 
After continued failure to separate using anion exchanger resins a Biotage® 
SNAP KP-C18 column was chosen. In order to prepare the sample for running 
on a Biotage® SNAP KP-C18 column it was first placed on a samplet pre-
column. When adding the product in DMF directly to a Biotage® samplet 
cartridge it would simply flow through. A dilution of the heme-DCCH product 
was made into 100x MeCN with 2% glacial acetic acid. This was added to the 
samplet, successively, which formed a tight brown band at the top of the 
samplet. By forming a tight band on the samplet the separation resolution was 
improved. Using MeOH as a running solvent, the C-18 column was able to 
separate the mod-heme from the free dye (Figure 3.19). This separation 
attempted to be improved upon by using solvents of decreasing polarity to better 
separate mono from bis product. The solutions used to wash the samplet were 7 
mM potassium phosphate buffered to pH 7.0 to deprotonate the one carboxylic 
acid on mono heme-DCCH in order to create a larger polarity difference 
between mono and bis heme-DCCH. This was followed by an MeCN gradient 
to 100% MeCN, which was followed by a gradient to 100% MeOH. Within the 
MeOH gradient the products would elute as one large peak (Figure 3.20). It was 
observed that later fractions contained pure bis heme-DCCH, which were 
collected and rotary evaporated. This procedure was performed eight more 
times, and all the total collected bis product was pooled together and re-
suspended in 300 µl of DMF. Calculating the percent yield gives an 
approximate yield of 3.1 %. This calculation was somewhat incorrect because 
the assumption was made that 100% of the heme-NHS was bis heme-NHS. This 
was known to not be true, as evidenced by MS. If it is assumed that the ratio of 
mono to bis heme-NHS was at worst 50%, bis heme-NHS the yield would be 
closer to 6.2%, which remained a poor yield. The primary issue with low yields 
was the extreme challenge of separating mono from bis product. Although the 
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reaction appeared to go to completion, upon separation much of the bis product 
was contaminated with the mono product. In the future a highly resolving 
technique may be more fruitful in obtaining bis heme-product, such as a C-18 
HPLC column.  
 
Figure 3.19: Heme-DCCH reaction separated on a Biotage® KP-C18-HS SNAP column using 
MeOH as a running solvent. There were three visible peaks (A). The second and third peaks were 
analyzed with MS. The second contained a mixture of mono and bis heme-DCCH (B), and the third 
peak appeared to contain no mono heme-DCCH (C).   
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Figure 3.20: Heme-DCCH separation on a Biotage® KP-C18-HS SNAP column using gradients of 
solvents with increasing polarity was used to try and better separate mono from bis heme-DCCH. 
There was only one large peak, rather than two distinct peaks observed (A). As fractions were 
sampled it was observed that the later eluting product was pure bis heme-DCCH (B) and the earlier 
was a mixture of mono and bis heme-DCCH (C). 
3.3.3.2. Heme-AAF Purification 
Heme-AAF was not purified to the same extent as heme-DCCH was, and 
Heme-AAF was simply separated away from only the reactants. Since the aim 
of this research was to establish whether or not mod-heme could be inserted into 
Bfr, less emphasis was placed on the isolation of mono and bis heme-AAF, 
which decreased the time spent exploring conditions and saved expensive 
fluorescent reagent. Heme-AAF was separated on LH-20 resin in 100 mM 
phosphate buffer at pH. 8.0. It was noticed that the Heme-AAF product was 
soluble in aqueous buffer, which was likely due to the solubility of AAF in 
buffered solutions over a pH of 6. This made incorporation into Bfr much more 
efficient. The product would elute as the first peak, which was collected and 
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then incorporated directly into Bfr. The incorporated heme-AAF in Bfr was 
analyzed with MS/MS, as outlined below.   
3.3.4. Mod-Heme Incorporation into Bfr 
3.3.4.1. Incorporation and Spectral Shift of Incorporated Mod-
Heme 
The mod-heme was incorporated into apo His6-tag Bfr (with no 
traceable amount of native heme) using a method derived from a previous 
publication.139 Bfr would be incubated with the desired mod-heme at 80 °C for 
10 minutes and then allowed to cool to room temperature. The incorporated 
mod-heme would then be separated from free mod-heme on a desalting GE 
SephadexTM G-25 Fine column with a buffered running solution of 50 mM Tris 
and 100 mM NaCl at pH 8.0.  Heme-AAF was used directly from the column 
purification, whereas bis heme-DCCH was in DMF solvent which was added 
directly to the protein solution (Figure 3.21). DMF caused some precipitation of 
apo His6-tag Bfr upon addition, and so incorporation rates were much lower. A 
red-shift of the heme Soret peak was observable both with chromatography and 
in the UV-Vis spectrum for both mod-hemes (Figure 3.21). This spectral shift 
was indicative of the methionine bi-coordination of heme within Bfr. If heme 
was not properly incorporated then this red-shift would not have been observed. 
The percent incorporation of heme-AAF was approximated to be close to 100%, 
evaluated with a Bradford assay and AAF extinction coefficients, whereas the 
percentage incorporation of bis heme-DCCH was approximately 2%. This large 
discrepancy was undoubtedly due to solubility issues experienced with bis 
heme-DCCH. The emission and excitation spectrums for the free fluorophore, 
mod-heme, and mod-heme incorporated in Bfr (Figure 3.22). The excitation and 
emission maxima did not seem to change between samples. 
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Figure 3.21: Purification of incorporated bis heme-DCCH (A) and heme-AAF (B) from 
unincorporated mod heme on a GE SephadexTM G-25 Fine resin. Fractions from these separations 
were collected and analyzed by UV-Vis spectroscopy. A control of unmod-heme was analyzed for the 
spectral red shift of the heme Soret band (C), which was observed as a 38 nm peak shift. This same 
spectral shift was observed for both the heme-AAF (D) and heme-DCCH (E) incorporated in Bfr. 
The absorption spectra of free AAF had a peak that matched that of the incorporated heme-AAF, 
and free DCCH absorption spectra matched that of the absorption spectra of incorporated bis heme-
DCCH. 
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Figure 3.22: The excitation and emission spectrums for free AAF, heme-AAF, and heme-AAF 
incorporated in Bfr (A), and free DCCH, bis heme-DCCH, and bis heme-DCCH incorporated in Bfr 
(B). 
3.3.4.2. MS/MS of Mod-heme Incorporated into Bfr 
Mod-heme incorporated within His6-tag Bfr was analyzed using 
MS/MS. After separating the incorporated mod-heme from the free mod-heme 
with a desalting column the mod-heme-Bfr construct was free of unincorporated 
mod-heme. Therefore, the mod-heme examined by MS/MS should be of heme 
derivatives which had been incorporated into Bfr. Bis heme-DCCH was purified 
and incorporated in such low quantities that it was unable to be analyzed by 
MS/MS. Instead, the highly available mixture of mono/bis heme-DCCH was 
used to incorporate within Bfr, which was analyzed with MS/MS. When 
examining incorporated mono/bis heme-DCCH an 873 peak corresponding to 
mono heme-DCCH was observed (Figure 3.23). This peak was fragmented with 
MS/MS and peaks corresponding to the loss of water, which indicated the 
presence of a carboxylic acid, and a 557 Da peak, as was seen with heme 
fragmentation, were observed. This indicated that heme-DCCH remained bound 
to His6-tag Bfr during chromatographic separation, and displayed the same 
fragmentation signature of mono heme-DCCH. It would be reasonable to 
suggest that heme-DCCH was present in Bfr to some extent. The same 
experimentation was performed with heme-AAF incorporated within Bfr, which 
again exhibited the presence of mono heme-AAF (Figure 3.24). This peak was 
fragmented using MS/MS experiments and peaks corresponding to a carboxylic 
acid cleavage and a 557 peak, as was seen for heme fragmentation, were both 
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observed. Again, this analysis suggested that heme-AAF was incorporated 
within His6-tag Bfr. In addition to these experiments native polyacrylamide gel 
electrophoresis (PAGE) and fluorescence evaluation were used to assess proper 
incorporation of the mod-hemes within Bfr.  
 
Figure 3.23: Detection of the mono heme-DCCH product (A) after incorporation into Bfr. This peak 
was fragmented and formed the same ions that were detected previously with mono heme-DCCH 
(B). 
 
Figure 3.24: Detection of the mono heme-AAF product (A) after incorporation into Bfr. This peak 
was fragmented and formed the same 557 peak observed with heme fragmentation, and a 985 peak 
corresponding to the loss of water from carboxylic acid (B). 
3.3.4.3. Native PAGE of Incorporated Mod-Heme 
His6-tag Bfr incorporated with bis heme-DCCH and heme-AAF were 
run on native PAGE to detect fluorescent mod-hemes associated with native 
protein structures (Figure 3.25). These gels were fluorescently imaged to detect 
the presence of bis heme-DCCH and heme-AAF, and then stained to detect the 
presence of associated protein. Clearly, fluorescent bands were visible at the top 
of the gel that were also stained blue by the protein specific coomassie stain. 
This result showed that both mod-hemes were associated with non-denatured 
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protein. The gel migration of the incorporated mod-hemes in His6-tag Bfr was 
identical to that of the incorporated unmod-heme His6-tag Bfr control. Free 
heme-AAF was also run as a control, which did not generate a fluorescent band 
at the same position. These observations indicated that the incorporated mod-
hemes seemed to be associated with the native protein structure. Anisotropy of 
these mod-heme incorporated samples was performed next to further 
demonstrate proper association of this heme labelled dye.  
 
Figure 3.25: Native-PAGE of mod-heme incorporated in Bfr. Native PAGE was run with free heme-
AAF (1), unmod-heme incorporated in Bfr (2), bis heme-DCCH incorporated in Bfr (3), and heme-
AAF incorporated in Bfr (4). The native PAGE was first imaged fluorescently without stain and then 
stained with coomassie. 
3.3.4.4. Fluorescence Anisotropy of Incorporated Mod-Heme 
Fluorescence anisotropy experiments were performed to compare the 
rotational freedom of the free fluorophore, the mod-heme, and the incorporated 
mod-hemes. Fluorescence anisotropy measures the rotational freedom by taking 
two measurements of light in perpendicular polarized planes. If the value is zero 
then there is total freedom of rotation, whereas if the anisotropy is 1 then the 
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fluorophore is totally restricted in movement. When measured, the heme-AAF 
incorporated in Bfr had a much higher anisotropy, 0.3, than the free AAF, 
0.034. This was consistent with values of other fluorescently labeled 
biomolecules.182,183 The free heme-AAF showed an anisotropy of 0.059, slightly 
larger than the free AAF, but much smaller than the incorporated heme-AAF. 
This indicated that heme-AAF must have been restricted within a large 
structure, which slowed the rotation. DCCH was not soluble in aqueous buffer, 
and so the anisotropy was not measured, but the bis-DCCH-heme incorporated 
in Bfr had an anisotropy of 0.33, comparable to that of incorporated heme-AAF.  
  In addition to these anisotropy measurements, a Perrin plot was used to 
evaluate the size of the rotating particle that contained the fluorophore. Sucrose 
was titrated into the sample in increments of 3% up until a final concentration of 
30% (Figure 3.26). When the volume of the rotating unit was calculated the size 
of the heme-AAF incorporated in Bfr was 10.5 nm, which was close to the 
actual size of 12 nm. The free AAF, and heme-AAF were 2.5 nm and 2.7 nm 
respectively. The size of the free fluorophore was much larger than expected 
based on the actual size of the fluorophore. This could be explained by 
resonance energy transfer (RET).184 Typically in Perrin plots the lines will 
intersect at a common point on the y-axes, which is the ro value.
182 If, as is 
known with fluorescein, there is RET between fluorophores it will cause a shift 
in the slope of the Perrin plot. This shift in the slope causes an overestimation of 
the true anisotropy value.185 This effect might explain why the unincorporated 
fluorophores seemed to be larger than they truly were. Free DCCH and free 
heme-DCCH could not be examined due to the insolubility of these molecules 
in aqueous buffer, which were not appropriate comparisons to bis DCCH-heme 
incorporated in Bfr.   
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Figure 3.26: A Perrin plot of free AAF, free heme-AAF, incorporated heme-AAF, and incorporated 
bis heme-DCCH. Each sample was titrated with sucrose from a 60% (w/v) solution of sucrose in 3% 
increments until a concentration of 30%. 
3.3.4.5. Heme-AAF Quenching  
Quenching experiments were performed, as was done with the SF 
quenching experiments. It was observed that the heme-AAF incorporated in Bfr 
showed the same quenching pattern as the encapsulated SF, both of which had 
fluorescein labels (Figure 3.27). The plot of quenching confirmed that the 
fluorophore was protected to the same extent as the encapsulated SF. With this 
evidence, and the previous evidence, it was suggested that modification of heme 
propionate groups with fluorophores and the proper incorporation into Bfr was a 
viable method to functionalize the Bfr platform. This initial work will lead to 
future modifications to heme propionate groups for the purpose of further 
functionalizing the inner surface of Bfr.   
 
Figure 3.27: Heme-AAF incorporated into Bfr was titrated with iodide (A) and dabsyl-glutamate 
(B), as encapsulated SF was in chapter2. Heme-AAF incorporated into Bfr showed the same 
quenching patterns as encapsulated SF.   
3.4. Conclusion  
Here it has been shown that heme was able to be chemically modified with 
multiple molecules, two of which were purified and incorporated into the Bfr 
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protein structure. It was discovered that the use of labels with hydrazide 
functionalities often led to unexpected and unwanted side reactions with the 
heme porphyrin group. As a precaution, such functionalities should be avoided 
in the future. DCCH and AAF were both attached to heme, but only DCCH was 
purified to its constituent mono and bis products, whereas heme-AAF was 
purified as a mixture. The product synthesis was evaluated with MS, and later 
by MS/MS fragmentation patterns of the mod-heme products. All products 
demonstrated the expected masses and fragmentation patterns, and thus it was 
highly probable that these were the desired products. Both mod-hemes were 
incorporated into Bfr, which were evaluated by chromatography, UV-Vis 
spectroscopy, MS, native PAGE, fluorescence anisotropy, and fluorescence 
quenching. The development of this aspect of the Bfr platform was seen as 
critical to design new functionalities within Bfr. The introduction of fluorescent 
markers, and affinity interactions to the heme will provide much more control of 
Bfr modification, and host-guest interactions.  
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Chapter 4: Future Directions  
4.1. Introduction 
Despite the work that has been performed to develop the Bfr 
bionanoplatform, there remains much work to explore the full extent of its 
capabilities. Three projects, outlined below, intend to further the developmemt 
of bacterioferritin and its applications. Furthering the heme work from chapter 3 
is essential to best develop Bfr. Heme is both an integral and unique aspect of 
Bfr, which provides a great advantage to this platform. Labelling heme with 
fluorophores has shown that it is possible to modify the heme and still 
incorporate it into Bfr. The next steps are to add functional groups that serve 
auxiliary functions to fluorescence, such as the lysine-NTA ligand explored, 
catalysts186, or imaging agents.187 Heme, in this sense, will act as a highly 
specific component for both localization to the inner surface and as a 
fluorescent marker. Unlike Cys or other amino acids that may be used to 
covalently attach functional groups onto proteins, heme can be manipulated 
outside of the protein environment98 prior to its incorporation into Bfr. In 
addition to the synthetic advantages to heme modification, it would become 
possible to mix differing ratios of modified heme to derive an ensemble of 
modified hemes within a single Bfr. Since Bfr contains 12 heme binding 
pockets, it would be possible to mix ratios of, say, fluorescently labeled heme, 
NTA modified heme, and gadolinium complexed-heme all to the same Bfr 
molecule. These aspects make heme an exciting, and interesting molecule to 
explore further. The first of these explorations will be the addition of lysine-
NTA to heme. 
The second aspect of Bfr yet to be explored is the exterior surface 
modification. Much has been accomplished in the development of the interior of 
Bfr, which, to paraphrase Jeroen J.L.M. Cornelissen, is far more difficult to 
modify than the exterior8, but little has been done to functionalize the exterior of 
Bfr. Exterior surface modification of ferritin has been accomplished in other 
publications, primarily in the drug delivery arena2,18,188, but also in some of the 
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work in bio-materials science.189-192 Designing specific labels on the surface of 
Bfr will enhance its range of applications.  
Lastly, development of Bfr as a platform for NP-based catalytic conversion 
of small molecules will be explored. This development will follow work 
previously performed by Varpness, Z. et. al.64. This will involve the synthesis 
and characterization of a Pt NP within Bfr along with its capabilities to produce 
H2 gas. By designing Bfr for this purpose, it will overcome the issues seen in 
the previous publication with Pt NP catalyst stability.  
4.2. Heme-lysine-NTA Incorporation into Bfr 
By adding an NTA functionality to heme the His6-tag-NTA interaction, 
used heavily in this thesis, would be reversed between host and guest. This 
reversal will dramatically change the range of proteinaceous guests that can be 
encapsulated within Bfr. His6-tags, which are commonly placed on proteins for 
expression purposes, could be used as the specific affinity ligand for 
encapsulating them within the host Bfr displaying an NTA functionality from its 
heme groups. Heme-lysine-NTA has already been synthesized, and now 
requires purification. Additional attempts to improve solubility of lysine-NTA 
in DMF or DMSO should be made, which may increase the reactivity with 
heme-NHS. Purification should be explored with both LH-20 and C-18 columns 
to try and separate heme from the mono heme product. The product should 
display enhanced solubility due to the addition of three carboxylic acid 
functional groups, as was exhibited with the heme-AAF product. This should 
improve the amount of heme-lysine-NTA able to be incorporated within Bfr. 
Presence of heme-lysine-NTA in Bfr should be evaluated using fragmentation 
with MS/MS to identify its presence with Bfr, and the heme Soret peak spectral 
shift upon insertion into Bfr, as outlined in chapter three.   
The first His6-tag bearing guest to be explored would be green fluorescent 
protein (GFP). GFP is another well-established protein in molecular biology. 
GFP is derived from jelly fish, is intrinsically fluorescent, has a molecular 
weight of 26854 Da, is 238 amino acids long, has a beta barrel fold, and is 
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approximately 5.2 nm long and 2.4 nm wide.193 This serves as an ideal guest 
molecule for encapsulation because it is relatively small, intrinsically 
fluorescent, and will contain a single His6-tag affinity ligand. GFP can be used 
in this manner as a guide for encapsulating other proteins with single His6-tag 
affinity interactions. Encapsulation procedures should entail declustering with 
varying concentrations of GndHCl and varying temperature, and exploration of 
different ratios of heme-lysine-NTA to native heme in Bfr. TEM and 
fluorescence analysis of the encapsulated GFP should be performed as with the 
SF encapsulation studies, outlined in chapter two. Study of GFP on this 
platform will surely lead to future encapsulation studies with enzymes and other 
functional proteins. By using the reversed His6-tag NTA interaction it will 
make the protein guests more similar in the nature of the affinity interaction. 
This should provide some consistency and continuity between the proteinaceous 
guest molecules and the host Bfr.   
4.3. Surface Modification of Bfr 
To better enable Bfr to act as a guest delivery platform it is considered 
critical to develop the outer surface as well. Some of this work has already 
begun with the design and preparation of an S-tagged Bfr, which was prepared 
on a plasmid by Anthony Petrie of the Honek laboratory. The S-tag was 
designed on the N-terminus, which faces the exterior, as mentioned in chapter 
two. Work has been done to express and purify this protein, as outlined in 
chapter two, and is currently being explored for labelling purposes by Hawa 
Gyamfi of the Honek laboratory. Reasons for exploring the S-tag are outlined in 
detail in chapter two.  
Alternative means to modifying the exterior surface of Bfr could be the 
covalent modification of a Cys residue. Fortuitously, there are no Cys amino 
acids coded for in the Bfr structure. A single point mutation in the structure 
could enable the specific labelling of 24 Cys residues in the fully assembled 
cage protein. Maleimide chemistry could be used to specifically label the Cys 
residues with fluorophores to evaluate this labelling method, which could later 
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be exchanged for other targeting ligands such as the RGD peptide.2,111  The 
point mutation would have to be chosen well in order to generate an exposed 
Cys residue on the surface. It would be ideal, as well, to choose a residue that is 
non-disruptive to the fold. A sequence alignment was performed to determine 
residues that were highly conserved in the Bfr structure. After looking at the Bfr 
crystal structure and a sequence alignment several candidate residues were 
chosen: Asp 73, Lys 76, Ser 89, and Ser 110. This method, in addition with the 
S-tag method would provide unique and highly specific functionalities for 
modification of the Bfr surface.  
4.4. Platinum Core Synthesis and H2 Gas Production 
Using and re-engineering the function of protein platforms has limitations. 
For instance, design of a drug delivery vehicle with intrinsic toxicity or toxic 
metabolic products would be unwise to explore as a platform in light of other, 
non-toxic, choices. Proper complementation of the desired function of a 
platform with its native capabilities would surely benefit the final application, 
and limit the number of potentially detrimental modifications. This reasoning 
follows the rule of parsimony, where the fewest number of modifications to a 
platform should lead to the lowest potential for ill effects on important structural 
or functional features. Through examination of Bfr as a platform for 
nanotechnology there remains one area not explored that would complement the 
proteins native function. This would be to exploit its native metal nanoparticle 
(NP) carrying capacity. Synthesis of a Pt NP in Bfr could be explored, 
mimicking research previously performed with a heat shock protein.64 This heat 
shock protein was approximately 12 nm in diameter, and 400-1000 atom Pt NPs 
were synthesized inside this cage protein. The researchers used methyl viologen 
and Tris(bipyridine)ruthenium(II) (Ru(bpy)3
2+) to produce electrons from a light 
source and transfer them to the Pt NP. The pores of the heat shock protein were 
large enough to allow the transfer of electrons from the methyl viologen 
mediator. The advantage of using the protein cage was that it prevented the 
aggregation of Pt NP. The researchers were able to use the Pt NP catalyst to 
produce H2 gas at reported levels of hydrogenases, but the production would 
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cease after a short period of time. This was thought to be due to the degradation 
of the electron mediator, methyl viologen, by Pt based hydrogenation. Since the 
pore size was large enough to allow methyl viologen to the interior space it 
could easily become hydrogenated by the catalyst. The problem here was to 
somehow get electrons to the Pt catalyst in order to produce H2 gas without 
degrading the electron mediator in the process. This is where Bfr is an ideal host 
for such a process, and could provide many advantageous features.  
 Bfr has pores that are already tuned for passage of only small molecules 
like water, iron and phosphate. These pores would only allow small molecules, 
like water or H2 gas to transit, whereas larger molecules would be generally 
excluded. This sieve could work to protect the catalyst from modifying 
molecules other than those desired. In addition to providing this unique 
advantage, Bfr could be used as a model to further develop the understanding of 
protein shell scaffolds. Recently, the importance of pore size was investigated 
examining the effects of protein shells and their pore size on the activity of Pt 
NPs for antioxidant activity.194 It was shown that the pore size and shell were 
important determinants for the catalytic properties of the Pt NP. By exploring 
this area with the Bfr protein shell it would further develop the understanding of 
how pores and the platform effect catalytic rates.   
Since methyl viologen was used to shuttle electrons to the Pt NP in the 
discussed publication, and Bfr would not allow direct contact of these two 
components, the natural question would be how does one move electrons into 
the Bfr interior without moving an electron mediator in? Bfr is well placed for 
this process because it has been found that electron movement across the protein 
shell is integral for the native processes. Bfr, along with all ferritin family 
proteins, is involved with iron storage and release in the cell. Regulation of the 
process of iron core formation and release has only recently been discussed.81,134 
In the process of reduction of iron for release from Bfr heme has been found to 
be the mediating cofactor for electron shuttling from the exterior to the 
interior.81 Important in this process was a Bfr associating ferredoxin protein 
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(Bfd), which is a small protein containing an Fe-S centre that transfers electrons 
from ferredoxin to the centre of Bfr through the heme cofactor. This mechanism 
provides a unique and exciting opportunity to re-purpose this function for 
another application. The heme cofactor could serve as a means to deliver 
electrons to a Pt NP without necessitating an electron mediator to come in 
contact with the Pt NP. By exploiting this electron transfer pathway, along with 
the complementary nature of Bfr as a metal NP host, a very stable, and long 
lasting H2 catalyst could be formed.  
 Using Bfr as a platform should be electrochemically viable since the 
redox potential of heme in Bfr is -225 mV82, whereas the redox potential of 
methyl viologen is -446 mV. The redox potential of Pt is known to be as high as 
700 mV, depending on the size of the particle.195 This could effectively shuttle 
electrons from the exterior environment to the interior environment, thus 
protecting the Pt NP from external factors. Bfd could also be used as a means to 
shuttle electrons through Bfr, although it might be possible to reduce the heme 
with an electron mediator such as methyl viologen. These options would have to 
be characterized for their electron transfer capability.    
 Although the goal of this research direction is to replicate Pt NP 
catalyzed H2 gas production, there will be milestones to meet, and each 
milestone will be independently impactful to the development and 
understanding of Bfr as a whole. These milestones are: evaluation of E. coli Bfd 
and the electron transfer characteristics to Bfr, and the synthesis of metal NP 
within Bfr and evaluation of their catalytic capabilities.   
4.4.1. Exploration of Bfd and its ability to Transfer Electrons to Bfr 
Heme 
Recently, work detailing the necessity of a Bfd protein for electron 
transfer and iron release in Bfr derived from Pseudomonas aeruginosa was 
published81. An E. coli gene with high sequence similarity for P. aeruginosa 
Bfd is known, however the crystal structure, and electrochemical evaluation of 
this E. coli protein has not been investigated. By cloning and expressing Bfd it 
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would provide necessary information on the physical characteristics of this 
protein along with its interaction with Bfr. A sequence would have to be 
generated, and placed on a plasmid for expression. It is possible to have this 
sequence generated by GenScript and placed on a plasmid for a nominal fee. 
Expression should be without issue since this is a native protein to the host E. 
coli bacteria that would be employed for it’s over expression. After expression 
the protein would need to be purified. Once pure, iron release characteristics 
should be analyzed to determine the electron transfer capability of E. coli Bfd, 
as was done previously.81 A co-crystallized structure of E. coli Bfr and Bfd 
could be of importance for the futher characterization of the interface between 
the two, and to compare against the known Pseudomonas aeruginosa structure. 
This study would be of significance because it could unite the Bfr protein 
family with a common Bfd architecture for liberating Fe atoms from the 
interior. In addition, Bfd investigation could provide a unique methodology for 
transferring electrons to the Bfr core for a variety of purposes.   
4.4.2. Synthesis of a Platinum Nanoparticles within Bfr and Analysis 
of its Catalytic Capabilities  
Finally, the production of Pt NP would be explored within Bfr. The 
advantages of exploring NP synthesis within Bfr would be: predictive NP 
growth, avoidance of deactivation of the catalytic surface and mediators, 
improvement of difficult catalytic NP recovery, and prevention of NP 
aggregation.n196 NPs would be synthesized as in previous publications with Pt 
in the presence of Bfr followed by reduction with sodium borohydride.64 The Pt 
NP would be synthesized in varying sizes to evaluate the effect of size on the 
catalytic function, as has been previously explored.194,196 The formation of these 
NP will be evaluated with TEM, and UV-Vis spectroscopy, as with the 
investigation of 5 nm GNP encapsulation in chapter two.  
Two methods would be explored for electron transfer to heme: Bfd 
reduction of heme, and methyl viologen reduction of heme. The advantage of 
exploring both methods is that each has different means of generating electrons. 
Methyl viologen can generate electrons from light using a Ru(bpy)3
2+ 
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cocatalyst, whereas Bfd get electrons from ferredoxin, which derives electrons 
from NADPH. This electron transfer to heme in Bfr could be evaluated using 
electron paramagnetic resonance.77 Evaluation of the ability to transfer electrons 
across the protein shell will provide evidence for the ability of Bfr to act as a 
nanoreactor for redox reactions. The production of H2 gas will be evaluated by 
the production of hydrogen gas via GC-MS. If the heme cofactor proves to be 
electrochemically inappropriate it may be possible to switch the heme cofactor 
for another porphyrin or chlorin, or to modify the methionine residues 
coordinating the heme.86,197 This work will push Bfr into applications with the 
potential to be a highly useful nanoreactor for fuel production and other 
catalytic functions.  
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Appendix 
Appendix  1: MS of Dabsyl-glutamate with the calculated mass using high resolution mass 
spectrometry with a Thermo Scientific Q-ExactiveTM. The calculated mass matched that of the 
expected molar mass for Dabsyl-glutamate, highlighted with the red arrow. 
  
 
Appendix  2: Possible labelling sites for fluorescein isothiocyanate. Possible lysine labelling sites per 
subunit are highlighted in blue. The lysines were Lys 80, 121, 132, and 134. The number of lysine 
residues that were labelled on SF was unknown, with a maximum number of 16 residues being 
labelled per fully formed tetramer. 
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